Cover Page  
Title: Pregabalin Plus Lofexidine for the Outpatient Treatment of Opi[INVESTIGATOR_224430]: [STUDY_ID_REMOVED]  
Document Name: [CONTACT_224605] D ate: 11/2/202 2 
1  
 
Protocol V9.0                                                                                                                           11/2/2022  Protocol  V-9.0                                                                                                                                                November  2, 202 2 
 
 
University of Pennsylvania  
 
 
 
Combining Pregabalin (LYRICA®) with Lofexidine (LUCEMYRATM): 
Can it Increase the Success of Transition to Naltrexone?  
 
 
Protocol Number: 
Regulatory Sponsor:  [ADDRESS_269847]  
Philadelphia, PA [ZIP_CODE]  
[PHONE_4737]  
 
Funding Sponsor:  National Institute on Drug Abuse 
National Institutes of Health  
[ADDRESS_269848] Room 5213  
Bethesda Maryland [ZIP_CODE]  
[PHONE_4738]  
Study Product:  Pregabalin  
Lofexidine  
Protocol Number:  9.0 
IND Number:  147130  
 
 
 
Date November 2, 2022 
2  
 
Protocol V9.0                                                                                                                           11/2/2022  1.0 SIGNATURE [CONTACT_224606] [CONTACT_31300], the University of Pennsylvania indicates approval of this protocol through the University 
of Pennsylvania’s IRB as well as assurance that this study will be conducted according to the procedures 
described in the protocol, ICH guidelines and Good Clinical Pract ices, and all applicable regulatory 
requirements.  
 
 
 
Printed Name [CONTACT_224607]’s Agreement  
I have received, read, and understood the information contained in the package insert for LYRICA 
(Pregabalin) and LUCEMYRA (lofexidine). I have read Protocol (IRB protocol number #) and agree to 
conduct the study as written in the protocol. I agree to maintain the confidentiality of all information 
received or developed in connection with this protoco l. 
 
 
 
 
Printed Name [CONTACT_224608]  V-9.0                                                                                                                                                                    November 2, 2022  
 
3  
 
Protocol V9.0                                                                                                                           11/2/[ADDRESS_269849] 
Philadelphia, PA 
[ZIP_CODE]  
[PHONE_854]  [EMAIL_890]  
George E. 
Woody, MD  Medical Monitor  [ADDRESS_269850] 
Philadelphia, PA 
[ZIP_CODE]  
[PHONE_760]  woodyg@ pennmedicine.upenn.edu  
Sabrina A. Poole, 
PsyD  Clinical Project 
Manager  [ADDRESS_269851] 
Philadelphia, PA 
[ZIP_CODE]  
[PHONE_763]  [EMAIL_4411]  
ECG Readings  
 
For UPENN:  
Kelly Spratt D.O., 
FACP, FACC  
 
For MOUNTAIN 
MANOR:  
Kelly Spratt, 
D.O., FACP, 
FACC  
 
For COLUMBIA:  
Kelly Spratt, 
D.O., FACP, 
FACC   
 
 
 
Cardiologist  Penn -Presby[CONTACT_224526]  
39th and Market 
Streets  
PHI Building, Suite 2A 
Philadelphia, PA 
[ZIP_CODE]  
Phone:  [PHONE_4739]  
Fax: [PHONE_4740]  
Cell: [PHONE_4741]   
 
[EMAIL_4412]  
Investigational 
Drug Service 
Central  Manufacturer/Distributor 
of Pregabalin/Placebo & 
Lofexidine  [ADDRESS_269852]., 
10th Flr., Philadelphia, 
PA [ZIP_CODE]  
Ph: [PHONE_4742]  
Fax [PHONE_4743]  [EMAIL_4413]  
Investigational 
Drug Service 
North  PPMC Dispensing 
Research Pharmacy  [ADDRESS_269853]., 
103 Mutch Bldg., 
Philadelphia, PA 
[ZIP_CODE]  
Ph: [PHONE_4744]  
Fax [PHONE_4745]  [EMAIL_4414]  
4  
 
Protocol V9.0                                                                                                                           11/2/2022  2.1 TABLE OF  CONTENTS  
 
1.0 SIGNATURE [CONTACT_1783]  …………………………………………………………………………………………….  2 
2.0 STUDY CONTACTS  …………………………………………………………………………………………….  3 
2.1 TABLE OF  CONTENTS   ……………………………………………………………………………………....  [ADDRESS_269854] OF TABLES    ………………………………………………………………………………………  [ADDRESS_269855] OF  FIGURES    ………………………………………………………………………………………  8 
3.0 PROTOCOL SUMMARY  ………………………………………………………………………………………  9 
4.0 SCHEMATICS  ………………………………………………………………………………………………….  12 
5.0 OVERVIEW OF STUDY ASSESSMENTS   ………………………………………………………………  [ADDRESS_269856] OF ABBREVIATIONS AND DEFINITIONS   ………………………………………………….……  17 
7.0 INTRODUCTIONS  …………………………………………………………………………………………….  18 
7.1 BACKGROUND  …………………………………………………………………………………………….  18 
7.1.2  DETOXIFICATION AND TRANSITION TO XR -NTX …………………………………………………….…  19 
7.1.3  DETOXIFICATION WITH BUPRENORPHINE  ………………………………………………………….….  19 
7.1.4  DETOXIFICATION WITH PREGABALIN  .…………………………………………………………………  19 
7.1.5  DETOXIFICATION WITH LOFEXIDINE  ……………………………………………………………..…..  20 
7.1.6  DETOXIFICATION WITH PREGABALIN AND  LOFEXIDINE……  ………………………………………….…  20 
7.2 INVESTIGATIONAL  AGENT……  …………………………...……………………..……………………………  21 
7.2.1  PREGABALIN STRUCTURE……………………  ………………………………………………………………..  21 
7.2.2  MECHANISM OF ACTION  ……………………………………………………………………………………..…  21 
7.2.3  PHARMACOKINETICS     …………………………………………………………………………  22 
7.2.4  ABSORPTION AND DISTRIBUTION  …………………………………………………………………………  22 
7.2.5  METABOLISM AND ELIMINATION  …………………………………………………………………………  22 
7.3 DOSE RATIONALE AND RISK/BENEFITS  ………………………………………………………………...  22 
7.3.1  MEDICATION AND BLINDING…  ……………………………………………………………………... ....………………… … ........................  22 
7.3.2  DOSING  SCHEDULES   ………..……………………………………………………………………………… .. 23 
7.3.3  DOSING GUIDELINES   …………………………………………………………………………………………  23 
7.3.4  POTENTIAL RISKS   ………………………………………………………………………………………..  24 
7.3.5  PREGABALIN ASSOCIATED AE’S  ……………………………………………………………………………  [ADDRESS_269857] COMMON AE’S LEADING TO DISCONTINUATION OF PREGABALIN  …………………………  [ADDRESS_269858] COMMON AE’S IN ALL PRE -MARKETING CONTROLLED PREGABALIN  …………………
…. 24 
7.3.8  AE’S LEADING TO DISCONTINUATION IN CONTROLLED TRIALS OF PREGABALIN  ……………..  24 
7.4 LOFEXIDINE  ………………………………………………………………………………………………….  26 
7.4.1  SAFETY  ………………………………………………………………………………………………………..  26 
7.4.2  METHADONE ………………………….  ……… . ……………………………………..………………………………  [ADDRESS_269859] COMMON LOFEXIDINE AES …… ..… …………………………………………………………………….  26 
7.4.4  ECG and VITAL SIGNS  …………………………………………………………………………………………………  26 
7.5 EXTENDED RELEASE NALTREXONE (XR -NTX)  …………………………………………………………  26 
7.5.1  INJECTION SITE REACTIONS  ………………………………………………………………………………  26 
7.5.2  PRECIPI[INVESTIGATOR_224431] -XR-NTX ………………………………  27 
7.5.3  NALTREXONE LIVER TOXICITY  …………………………………………………………………………  27 
7.5.4  NALTREXONE HEPATIC IMPAIRMENT  ……………………………………………………………………
. 27 
7.5.5  NALTREXONE GASTROINTESTINAL EFFECTS  …………………………………………………………
. 27 
7.5.6  NALTREXONE RENAL IMPAIRMENT  ……………………………………………………………………..
. 27 
7.5.7  NALTREXONE AND GENDER  ……………………………………………………………………………….  27 
7.5.8  NALTREXONE AND DRUG -DRUG  INTERACTIONS  ………………………………………………………
. 27 
7.5.9  NALTREXONE AND REVERSAL OF BLOCKADE FOR PAIN MANAGEMENT  ………………………….  27 
5  
 
Protocol V9.0                                                                                                                           11/2/2022  7.5.10  NALTREXONE AND DEPRESSION AND SUICIDALITY  ………………………………………………..  28 
7.5.11  NALTREXONE CONTRAINDICATIONS  …………………………………………………………………
. 28 
7.5.12  OPI[INVESTIGATOR_224432] -NTX BLOCKADE…………….     28 
7.5.13  EOSINOPHILIC PNEUMONIA   …………………………………………………………………….….....  28 
7.5.14  DATA FROM THE RUSSIAN XR -NTX STUDY OF OPI[INVESTIGATOR_224433] ………………                   28 
 8.0 STUDY OBJECTIVES   ……………………    28 
8.1 PRIMARY OBJECTIVES   …………………………………………………………………………….…  28 
8.2 SECONDARY OBJECTIVES  …………………………………………………………………………………  28 
8.3 ASSESSMENT TOOLS USED TO ACHIEVE OBJECTIVES  ……………………………………………  29 
9.0 STUDY DESIGN  ……………………………………………………………………………………………..  29 
9.1 GENERAL DESIGN  ……………………………………………………………………………………………  29 
9.1.1  PHASE 1 : OUTPATIENT PRESCREENING (DAY -7 TO DAY -1) ………………………………………  29 
9.1.2  PHASE 2 : INPATIENT RANDOMIZATION AND DOSING (DAY 1 THRU DAY 7)  …………………
… 30 
9.1.3  PHASE 3 : INPATIENT XR -NTX DOSING (DAY 8  OR 9 ) …………………………………………………     30 
9.1.4  SUBJECTS WHO REMAIN INPATIENT  …………………………………………………………………  31 
9.1.5  PHASE 4 : OUTPATIENT FOLLOW -UP VISITS (DAY 10 AND DAY 15) AT CLINIC VISIT  ……………..  31 
9.1.6  OPTIONAL F/U DAY (SECOND XR -NTX INJECTION…………………………………… …..  32 
9.2 PRIMARY STUDY OUTCOME ENDPOINTS  ………………………………………………………………  32 
9.3 PRIMARY SAFETY OUTCOME ENDPOINTS  ………………………………………………………….…  [ADDRESS_269860] SELECTION AND DISCONTINUATION  ……………………………..………………… .…....  33 
10.1 INCLUSION CRITERIA   ……………………………………………………………………………….…… .… 33 
10.2 EXCLUSION CRITERIA …………………………………………………………… ...  ……………………………  [ADDRESS_269861] RECRUITMENT AND SCREENING ............................................   ……………………………  34 
10.3.1  PARTICIPATING CLINICS OR DATA COLLECTION CENTERS .......................   …………………………….  34 
10.3.2  STUDY TIME TABLE ……………………………………………………………… ..…  ……………………………  34 
10.3.3  ENROLLMENT PROJECTIONS …………………………………………………….   ……………………………  35 
10.4 TARGET POPULATION DISTRIBUTION (GENDER, RACE, ETC …………… .....  ……………………………  35 
10.5 RECRUITMENT OF FEMALE SUBJECTS ……………………………………... ..…  ……………………………  35 
10.6 OBTAINING INFORMED CONSENT …………………………………………… .…  ……………………………  36 
10.7 SCREEN FAILURES ……………………………………………………………… .…  ……………………………  36 
10.8 EARLY WITHDRAWAL OF SUBJECTS ………………………………………… ….  ……………………………  36 
10.9 FOLLOW -UP OF WITHDRAWN SUBJECTS ………………………………….…..   ……………………………  37 
10.9.1  FOLLOW -UP OF SUBJECTS WHO NEED SECOND INJECTIONS ……………...   ……………………………  37 
10.10  DATA COLLECTION ……………………………………………………………….…   ……………………………  37 
10.10.1  DATA HANDLING & RECORD KEEPI[INVESTIGATOR_1645] ………………………………………….   ……………………………  37 
10.10.2  SOURCE DOCUMENTS ……………………………………………………………..   ……………………………  37 
10.10.3  CASE REPORT FORMS (CRFs) …………………………………………………….   ……………………………  37 
10.11  STUDY MEASURES ………………………………………………………………….   ……………………………  38 
10.12  SAFETY ASSESSMENTS ……………………………………………………………   ……………………………  39 
10.13  PROTECTION OF SUBJECTS ………………………………………………………   ……………………………  41 
10.13.1  VENIPUNCTURE ………………………………………………………………………   ……………………………  41 
10.13.2  RISKS ASSOCIATED WITH STUDY PROCEDURES ……………………………   ……………………………  41 
10.13.3  RISK BENEFIT RATIO ………………………………………………………………..   ……………………………  41 
10.13.4  MEDICAL MANAGEMENT OF ADVERSE EVENTS   ……………………………  41 
11.0 METHODS FOR ASSIGNING SUBJECTS TO TREATMENT GROUPS   ……………………………  41 
11.1 RANDOMIZATION …………………………………………………………………….   ……………………………  41 
11.2 RANDOMIZATION OF PLACEBO AGENT …………………………………………   ……………………………  42 
11.3 BLINDING OF STUDY DRUG ……………………………………………………….   ……………………………  42 
6  
 
Protocol V9.0                                                                                                                           11/2/2022  11.4 RECEIPT OF XR -NTX………………………………………………………………..   ……………………………  42 
11.5 RECEIPT OF NALOXONE ……………………………………………………………   ……………………………  42 
11.6 PREPARATION AND ADMINISTRATION OF STUDY  DRUG …………………..   ……………………………  43 
11.7 COMFORT  MEDICATIONS …………………………………………………………..   ……………………………  43 
11.8 PRIOR AND CONCOMITANT  MEDICATIONS …………………………………….   ……………………………  43 
11.9 RULING OU T CURRENT PHYSIOLOGIC DEPEND  BEFORE XR -NTX ADMINIS TRATION  …………  ….. 43 
12.0 RECEIVING, STORAGE, DEPENSING AND RETURN …………………………..   ……………………………  44 
12.1 RECEIPT OF PGB, LFX, AND XR -NTX…………………………………………….   ……………………………  44 
12.2 STORAGE OF INVESTIGATIONAL MEDICATION ……………………………….   ……………………………  44 
12.3 DISPENSING OF INVESTIGATIONAL MEDICATION ……………………………   ……………………………  45 
12.4 RETURN AND DESTRUCTION OF STUDY DRUG ………………………………   ……………………………  45 
12.5 DISPENSING XR -NTX……………………………………………………………….   ……………………………  45 
12.6 STUDY DRUG ACCOUNTABILITY ………………………………………………….   ……………………………  45 
13.0 STATISTICAL PLAN ………………………………………………………………….   ……………………………  46 
13.1 DATA ANALYSIS ………………………………………………………………………   ……………………………  46 
13.2 SAMPLE SIZE DETERMINATION …………………………………………………..   ……………………………  46 
13.3 STATISTICAL METHODS …………………………………………………………….   ……………………………  46 
13.3.1  PRIMARY OUTCOME …………………………………………………………….…..   ……………………………  46 
13.3.2  SECONDARY OUTCOMES ………………………………………………………… ...  ……………………………  47 
13.4 SAFETY OUTCOMES ………………………………………………………………   ……………………………  47 
13.4.1  SUICIDALITY …………………………………………………………………………...   ……………………………  47 
13.4.2  SEDATION ……………………………………………………………………………..   ……………………………  47 
13.4.3  ELEVATED CREATINE KINASE …………………………………………………….   ……………………………  47 
13.4.4  EDEMA …………………………………………………………………………………   ……………………………  47 
13.5 TOLERABILITY OUTCOMES ………………………………………………………..   ……………………………  47 
13.5.1  ACHINESS ………………………………………………………………………………   ……………………………  47 
13.5.2  ANXIETY ………………………………………………………………………………..   ……………………………  47 
13.5.3  INSOMNIA ……………………………………………………………………………….   ……………………………  [ADDRESS_269862] POPULATION FOR ANALYSIS …………………………………………   ……………………………  48 
13.7 ADVERSE EVENT RECORDING AND REDCAP SYSTEM ENTRY   ……………………………  48 
13.8 VITAL SIGNS …………………………………………………………………………..   ……………………………  48 
14.0 DATA MANAGEMENT ………………………………………………………………..   ……………………………  48 
14.1 DATA ACQUISITION AND TRANSMISSION ………………………………………   ……………………………  48 
14.1.1  DATA ENTRY METHODS …………………………………………………………….   ……………………………  48 
15.0 SAFETY AND ADVERSE EVENTS …………………………………………………   ……………………………  49 
7  
 
Protocol V9.0                                                                                                                           11/2/2022  15.1 DEFINITION OF  ADVERSE  EVENTS  …………………… ……………………..……………..  49 
15.2 ADVERSE EVENT REPORTING PERIOD  ……… …………… …………………………. …………. … [ADDRESS_269863] STUDY AEs  …………………………………………..…………………………  49 
15.4 ABNORMAL LABORATORY  VALUES  ………………………………………………… ……… …… 49 
15.5 HOSPI[INVESTIGATOR_55108], PROLONGED HOSPI[INVESTIGATOR_55108] & SURGERY  ………………… …………….  49 
15.6 RECORDING AEs  …………………………………………..………………………………..  50 
15.7 REPORTING SERIOUS ADVERSE EVENTS  ………………………………… ……………..………… . 50 
15.8 STUDY SPONSOR AND MEDICAL MONITOR NOTIFICATION BY [CONTACT_9929]   …………. …………  50 
15.9 REPORTING DEATHS  …………………………………………..……………………………  51 
15.10  OTHER REPORTABLE EVENTS  …………………………………………..…………………..  51 
15.11  IRB NOTIFICATION BY [CONTACT_9929]  ……… …………………………………..……  51 
15.12  FDA NOTOFICATION BY [INVESTIGATOR_206768]  …………………………………………..………………..  51 
16.0 STUDY MONITORING/AUDITING/AND  INSPECTION  …………………………………………..  52 
16.1 STUDY INITIATION  …………………………………………..…………………………..  52 
16.2 MONITORING VISITS  …………………………………………..……………… …………..  53 
16.3 MONITORING LOG  …………………………………………..……………… …………..  53 
16.4 MONITORING REPORT  …………………………………………..……………… …………..  53 
16.5 VISIT 4: CLOSEOUT  …………………………………………..…………… ……………..  53 
17.0 MEDICAL MONITORING  …………………………………………..…………… …..…………  53 
17.1 SAFETY AND MEDICAL MONITORING  ………………………………………..… ….….………  53 
18.0 ETHICAL CONSIDERATIONS AND SAFETY  ………………………………………..…… …...………  54 
18.1 GOOD CLINICAL PRACTICE (GCP)  ………………………………………..…… …...………  54 
18.2 MEDICAL EMERGENCIES  ………………………………………..…… …...………  54 
18.3 UNBLINDING PROCEDURES  ………………………………………..…… …...………  54 
19.0 STOPPI[INVESTIGATOR_224434]  ………………………………………..…… …...………  54 
19.1 STUDY STOPPI[INVESTIGATOR_127377]  ………………………………………..… …..….………  54 
19.2 MEDICATION DISCONTINUATION CRITERIA  ………………………………………..…….…………..  [ADDRESS_269864] STIPEND AND REIMBURSEMENTS  ………………………………………..…….……………  55 
21.0 POTENTIAL BENEFITS  ………………………………………..…….……………  57 
22.0 CONFIDENTIALITY  ………………………………………..…….……………  57 
22.1 HIPAA COMPLIANCE  ………………………………………..…….……………  57 
23.0 INDEPENDENT  ………………………………………..…….……………  58 
23.1 DESCRIPTION  ………………………………………..…….……………  [ADDRESS_269865] MEMBER QUALIFICATIONS  ………………………………………..…….……………  58 
24.0 DSMP STUDY MONITORING PLAN  ………………………………………..…….……………  59 
25.0 COVID SAFETY PLAN  ………………………………………..…….……………  59 
26.0 AUDITING AND INSPECTING  ………………………………………..…  61 
27.0 FUNDING SOURCE  ………………………………………..…….……………  [ADDRESS_269866] IN THE 
DSM  ………………………………………..…….……………  61 
29.0 PUBLICATION PLAN  ………………………………………..…….……………  61 
    
8  
 
Protocol V9.0                                                                                                                           11/2/2022  30.0 REFERENCES  ………………………………………..…….……………  62 
    
31.0 APPENDICES  (not attached per co pyright)  ………………………………………..…….……………  66 
 MINI -INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW (M.I.N.I.) FOR DSM 5 (SHEEHAN, 1998)  ……………   
 CLINICAL GLOBAL IMPRESSION SCALE (CGI; GUY,1976)  ……………   
 HAMILTON ANXIETY RATING SCALE (HAM -A; HAMILTON, 1959)  ……………   
 HAMILTON DEPRESSION RATING SCALE (HAM -D; HAMILTON, 1960)  ……………   
 INSOMNIA SEVERITY INDEX (ISI; BASTIEN, 2001)  ……………   
 OPI[INVESTIGATOR_224435] (VAS; MCMILLAN & GILMORE -THOMAS 1996)  ……………   
 PASERO OPI[INVESTIGATOR_136461] -INDUCED SEDATION SCALE (POSS; PASERO, 2009)  ……………   
 SUBJECTIVE OPI[INVESTIGATOR_112995] - GOSSOP (SOWS -G VERNON, 2015)  ……………   
 CLINICAL OPI[INVESTIGATOR_112995] (COWS; WESSON & LING, 2003)  ……………   
 TIMELINE FOLLOW -BACK INTERVIEW (TLFB; SOBELL & SOBELL, 1995)  ……………   
 COLUMBIA SUICIDE SEVERITY RATING SCALE (C -SSRS) RISK ASSESSMENT VERSION (POSNER 
ET AL., 2008)  ……………   
    
    
32.[ADDRESS_269867] OF TABLES    
33.0 TABLE 1. OVERVIEW OF STUDY ASSESSMENTS  ………………………………………..…….……  13 
34.0 TABLE 2. LOFEXIDINE DOSING  ………………………………………..…….……  23 
35.0 TABLE 3. PREGABALIN AND PREGABALIN -PLACEBO 
DOSING  ………………………………………..…….……  23 
36.0 TABLE 4. AEs IN TRIALS OF NEUROPATHIC PAIN  ………………………………………..…….……  25 
37.0 TABLE 5. CLINICAL LABORATORY TESTS  ………………………………………..…….……  [ADDRESS_269868] STIENDS AND 
REIMBURSEMENTS  ………………………………………..…….……  [ADDRESS_269869] STIENDS AND 
REIMBURSEMENTS  ………………………………………..…….……  [ADDRESS_269870] STIENDS AND 
REIMBURSEMENTS  
 
 ………………………………………..…….……  [ADDRESS_269871] OF FIGURES    
40.1 FIGURE 1. STUDY SCHEMATICS  ………………………………………..…….……  12 
42.0 FIGURE 2. MOLECULAR STRUCTURE OF PREGABALIN  ………………………………………..…….……  21 
43.0 FIGURE 3. PROJECTED TIME TABLE  ………………………………………..…….……  34 
44.0 FIGURE 4. ENROLLMENT PROJECTIONS  ………………………………………..…….……  35 
    
 
 
 
 
 
9  
 
Protocol V9.0                                                                                                                           11/2/2022   
Title Combining Pregabalin (LYRICA®) with Lofexidine (LUCEMYRATM): Can it 
Increase the Success of Transition to Naltrexone?  
Short Title  Pregabalin and Lofexidine for opi[INVESTIGATOR_224436]  7.0 
Phase  Phase 2  
Methodology  Double -blind placebo -controlled parallel group clinical trial  
Study Duration  24 months  
 
Study Centers (3)  • University of Pennsylvania Center for Studies of Addiction in 
Philadelphia  Pennsylvania  
• Columbia University in [LOCATION_001] City, New  York 
• Mountain Manor in Baltimore,  Maryland  
 
Objective 
(Primary)  
 
Objective 
(Secondary)   
To investigate whether pregabalin -Lyrica® (PGB) combined with Lofexidine -
Lucemyra ® (LFX) can reduce opi[INVESTIGATOR_43351] -related subjective effects  
 
To investigate, if the PGB/LFX combination can increase the proportion of 
patients with an opi[INVESTIGATOR_2427] (OUD) who complete detoxification and 
transition to antagonist treatment with extended - release injectable naltrexone 
VIVITROL® (XR -NTX)  
Number of Subjects  90 subjects. 60 randomized to PGB/LFX; 30 to PGB -PLA/LFX  
 
 
 
 
 
 
 
 
 
Inclusion Criteria  • Male and/or female subjects ≥ 18 years of  age 
• Meet DSM -[ADDRESS_269872] 12 
months  
• Interested in opi[INVESTIGATOR_224437]  
• Have used opi[INVESTIGATOR_27262] [ADDRESS_269873] 30  days  
• Have a stable address in the local area; not planning to move; 
have documents for ID  check  
• Absence of medical or psychiatric conditions that are likely to 
interfere with study  participation  
• Have a 12 lead ECG demonstrating a QTc ≤450 msec and a 
QRS  interval ≤120 msec . The site PI [INVESTIGATOR_224438] a question 
of QT prolongation or other factors  (QTc/Fri uses the Fridericia  
formula ( QTc = QT/RR(1/3) ).  If consultation is needed, the PENN 
cardiologists and the medical monitor  should be  contact[INVESTIGATOR_530] . 
• If female, have a negative pregnancy test, and uses adequate 
contraception if of childbearing potential  
 
 
 
Exclusion Criteria  • Current psychotic disorder (bipolar I, schizophrenia, major 
depression with psychotic features,) as defined by [CONTACT_224527]  
• An alcohol, benzodiazepi[INVESTIGATOR_050], or other sedative disorder with 
physiological features that require medication for  detoxification  
• History of allergy or other serious adverse event due to treatment with 
pregabalin, XR -NTX, or  lofexidine  3.0 PROTOCOL SUMMARY  
 
10  
 
Protocol V9.0                                                                                                                           11/2/2022   • Pending incarceration in the next 30  days  
• Homicidal or otherwise behaviorally disturbed requiring immediate 
attention.  
• High Risk for suicide as determined by [CONTACT_49419] ‘yes’ to questions 
4 and/or 5 on C-SSRS at  screening  
• Blood pressure <90 mm Hg (systolic) or <60 mm Hg (diastolic). If this value 
is out of normal range, the investigator and a study clinician will decide 
subject inclusion or exclusion  on a case -by- case basis  
• Heart rate  and/or pulse <50 bpm at  screening -sitting  
• An Estimated Glomerular Filtration Rate eGFR<90  mL/min/1.73m2 
• A history of, or current  seizure disorder (excluding  childhood  
febrile seizures)  
• Inability to read and/or understand English. For example, does not 
understand the informed consent as demonstrated by [CONTACT_224528] 
9/10 questions correctly on the  quiz 
• Pregnant or  breastfeeding  
• Currently taking sympathomimetic drugs, or a thiazolidinedione 
antidiabetic  
• An ALT and/or AST that is at > 4X the top limit of  normal  
• A Child -Pugh score  >7 
• Currently receiving opi[INVESTIGATOR_224439]  
• In a treatment study where medication was administered in the 
last 30  days.  
• Currently using medications that are known to be strong or moderate 
inhibitors of CYP2D6 such as fluoxetine, paroxetine, mirabegron, 
bupropi[INVESTIGATOR_2394], quinidine, terbinafine, cimetidine, cinacalcet, duloxetine, 
or fluvoxamine  
• In a methadone maintenance or buprenorphine treatment 
program within the last [ADDRESS_269874], Dose, 
Route, Regimen   
Pregabalin (PGB) or PGB -PLA given orally at a starting  dose of up to 400 mg 
on day 1, up to 600 mg daily on Day 2 through Day 4, tapered to 100 mg daily 
by [CONTACT_2006] 7; Lofexidine (LFX) starts at 1.62 mg on day 1, 2.16 Day 2 through Day 
4, tapering to 0.72 mg by [CONTACT_2006] 7.  After starting dose on Day 1, both study drug 
doses can be reduced or withheld depending upon patient ’s clinical 
observations for Days [ADDRESS_269875] the 
inpatient detoxifi cation program.  
Comfort Medications   
The following “comfort” medications are suggested for treatment of withdrawal 
symptoms that are not suppressed by [CONTACT_224529]:  ondansetron 4 mg or 
8 mg tid PO PRN  for nausea  and vomiting , trazodone 100 mg HS PRN 
insomnia, loper amide 2 mg qid PO PRN diarrhea , and a non-steroidal  such as 
Ibuprofen 600 mg qid PO PRN for aches and pains or acetaminophen  650 mg 
(2 tablets 325 mg) PO qid PO PRN ,  cyclobenzaprine  5 mg tid PO PRN  for 
muscle aches and pain s, and hydroxyzine 25 mg qid PO PRN  anxiety . In cases 
of QTc prolongation that are not >550ms or judged to require stoppi[INVESTIGATOR_224440], diphenhydramine 50  mg hs PO PRN  may be used for insomnia , 
and  trimethobenzamide  300 mg qid PO PRN  for nausea.  
11  
 
Protocol V9.0                                                                                                                           11/2/[ADDRESS_269876] of  
the 30 days prior to inpatient admission for study detoxification and treatment. On 
day 1 of inpatient treatment subjects will be randomized to PGB/LFX or PGB -
PLA/LFX for a 7 -day detoxification. On day 8, if the patient completes 
detoxification, continues to be interested in XR -NTX treatment , provides a urine , 
and passes a naloxone challenge, he/she will be offered one injection of XR -NTX 
before hospi[INVESTIGATOR_2345]. This injection of XR -NTX is optional. If retests must be 
done, such as a repeat of  the nalox one challenge, all subjects are eligible to 
remain inpatient  until Day 9. All subjects, whether they receive XR -NTX or not, 
will be referred to continuing care and asked to return to the research outpatient 
clinic on days 10 and 15 for follow -up visits. Subjects who cannot find a provider 
may be  offered an additional XR -NTX injection up to 5 weeks after the Day 8 
injection.  
Reference therapy  PGB -Placebo plus lofexidine  
 
 
 
 
 
 
Statistical 
Methodology  The primary outcome is reduction in subjective withdrawal as measured 
twice/day using the Short Opi[INVESTIGATOR_2433] (SOWS - Gossop). SOWS 
scores range from zero to 30. Groups will be compared on [ADDRESS_269877] treatment, with levels (1) failure to complete detox, (2) 
completion of detox with failure to receive antagonist treatment, and (3) 
completion of detox and receipt of  antagonist treatment.  
 
 
Note: Study medication will be provided in blister packs that are prepared by [CONTACT_224530]. For the University of Pennsylvania, e ach blister pack 
will have a patient randomization number and the dosing schedule for each time on each inpatient 
study day, as summarized in the Study Schematics 4.0 below. For the two external sites, patient 
randomization will be generated by [CONTACT_224531], who receives 
the blister packs from the PENN Investigational Drug Service with the dosing schedule for each day.   
 
The doses for each time of each day will be in separate compartments . Lofexidine will be 0.18 mg pi[INVESTIGATOR_224441]; pregabalin or pregabalin placebo will be in capsules.  Blue capsules will contain 100 mg 
pregabalin or placebo; green capsules will contain [ADDRESS_269878] from lofexidine is hypotension and/or bradycardia. The most 
likely side effect from pregabalin is sedation. Thus, in the event of hypotension, the next scheduled 
dose of lofexidine can be reduced or withheld. A similar adjustment can be made for excessive 
sedation (POSS score of 3 or 4; difficult to arouse, slurred speech , etc.) For the PENN site, medication 
counts will be done by [CONTACT_21212] (IDS) pharmacy for each subject. For sites 
outside PENN, medication counts will be done by [CONTACT_224532].  
  
12  
 
Protocol V9.0                                                                                                                            11/2/2022   
UDS, fentanyl  UDS, 
fentanyl  
UDS, 
fentanyl  
13  
 
Protocol V9.0                                                                                                                            11/2/2022  5.0 Table 1. Overview of Study Assessments  
 
 
Assessment  Outpatient  Inpatient  Inpatient  Inpatient      Inpatient  Outpat  Outpat  EOS /
AMA  
VISIT  
(early)  
 Screen    Day 1  Day 2     Day 3     Day 4    Day 5     Day 6  Day 7  Day 8/9†(all 
assessments  
Done both days  
Unless otherwise  
Stated) Day 10  
+2 business 
days EOS Day 
15 
+2 business 
days  
            
            
            
Informed Consent  1X            
Locator Information  1X         1X   
Medical History  1X            
Physical/Weight  1X          1X 
 1X 
 
CBC* with Diff and PLT,  
INR 1X         1X 
INR 
Not 
repeated  1X if no D10  
No INR 1X  
No INR  
Blood Chemistry, with 
Magnesium and Calcium  1X         1X 
Magnesiu
m not 
repeated  CMP 1X  
IF No Day 10   1X 
No 
magnesiu
m 
Creatine Kinase  1X        1X 
(done at D8 - 
only)    1X 
Estimated 
Glomerular Filtration  1X            
Child Pugh Score  1X            
Urinalysis with Reflex 
Microscopy  1X         1X  1X 
Urine Pregnancy Test - F 1X 1X       1X (if done 
at D8 -do not 
repeat on 
D9)  1X 1X 
UDS  1X 1X       1X 1X 1X    1X 
14  
 
Protocol V9.0                                                                                                                            11/2/2022  Assessment  Outpatient  Inpatient  Inpatient  Inpatient      Inpatient  Outpat  Outpat  EOS /
AMA  
VISIT  
(early)  
 Screen    Day 1  Day 2     Day 3     Day 4    Day 5     Day 6  Day 7  Day 8/9†(all 
assessments  
Done both days  
Unless otherwise  
Stated) Day 10  
+2 business 
days EOS Day 
15 
+[ADDRESS_269879]  1X         1X 1X  
HEP B & C  1X            
ECG  1X 1X 1X 1X 1X 1X 1X 1X     
 
MINI  1X            
Inclusion/Exclusion  1X            
Randomization Form  1X            
Visual Analog Scale for 
Craving   2X 2X 2X 2X 2X 2X 2X 1X    
Insomnia Severity Index  1X 1X 1X 1X 1X 1X 1X 1X 1X 1X 1X  
SOWS -Gossop  1X 2X 2X 2X 2X 2X 2X 2X 1X 1X 1X  
COWS  1X 2X 2X 2X 2X 2X 2X 2X 2X 1X 1X  
POSS   3X 4X 4X 4X 4X 4X 4X 1X    
Naloxone Challenge 
(optional; only if pt. is 
interested and  
detoxed)          1X 
(if 
positive 
on D8-
repeat on 
D9)   1X 
Can be 
given to 
AMA Pts  
XR-NTX         1X 
(if not 
done D8 -
do on D9)    1X 
Can be 
given to 
AMA Pts  
Vital Signs Cont’d next pg.  
 1X 8X 8X 8X 8X 8X 8X 8X 1X BP 
sitting only  1X BP 
sitting 1X BP 
sitting only  1X BP 
sitting 
15  
 
Protocol V9.0                                                                                                                            11/2/2022  Assessment  Outpatient  Inpatient  Inpatient  Inpatient      Inpatient  Outpat  Outpat  EOS /
AMA  
VISIT  
(early)  
 Screen    Day 1  Day 2     Day 3     Day 4    Day 5     Day 6  Day 7  Day 8/9†(all 
assessments  
Done both days  
Unless otherwise  
Stated) Day 10  
+2 business 
days EOS Day 
15 
+2 business 
days  
            
            
            
(BP-sitting & standing); 
Pulse  only  
  only  
 
Adverse Events   1X 
@each  
visit 1X 
@each 
visit 1X 
@each 
visit 1X 
@each 
visit 1X 
@each 
visit 1X 
@ea
ch 
visit 1X 
@each 
visit 1X 
@visit  1X 
@visit  1X 
@visit  1X 
@visit  
Serious Adverse Events   1X 
@each  
visit 1X 
@each 
visit 1X 
@each 
visit 1X 
@each 
visit 1X 
@each 
visit 1X 
@ea
ch 
visit 1X 
@each 
visit 1X 
@visit  1X 
@visit  1X 
@visit  1X 
@visit  
Concomitant Medications  1X 1X @each  
visit 1X @each 
visit 1X @each 
visit 1X @each 
visit 1X@each 
visit 1X @each  
visit 1X @each 
visit 1X 
@visit  1X 
@visit  1X 
@visit  1X 
@visit  
Comfort Medications   1X 
@each  
visit 1X 
@each 
visit 1X 
@each 
visit 1X @each  
    visit 1X @each  
       visit 1X @each  
      visit 1X @each  
      visit 1X 
@visit  1X 
@visit  1X 
@visit   
TLFB -
90 1X            
TLFB -2-wk           1X  
Clinical Global 
Impression Scale 
(CGI)  1X        1X  1X 1X 
HAM -D 1X        1X  1X  
HAM -A 1X        1X  1X  
C-SSRS  1X 1X 1X 1X 1X 1X 1X 1X 1X 1X 1X  
Lofexidine/Pregabalin*
* Adherence Pi[INVESTIGATOR_212434]   1X 1X 1X 1X 1X 1X 1X     
XR-NTX Adherence          1X    
End of Study Form 
(EOS)    1X 1X 1X 1X 1X 1X 1X 1X 1X 
 1X 
 
 
                  EOS only completed 1x when subject completes or drops from study at last study visit  
16  
 
Protocol V9.0                                                                                                                            11/2/2022  ECG=electrocardiogram (QT /Fri corrected for heart rate with Fridericia  formula ( QTc = QT/RR(1/3) ); *CBC=complete blood count with diff ; 
PLT, INR (INR at screen only) ; Chemistry for magnesium need not be done at Day 10 ; DSM -5=Diagnostic and Statistical Manual of 
Mental Disorders, Fifth Edition ; COWS=Clinical Opi[INVESTIGATOR_9721] ; SOWS=Short Opi[INVESTIGATOR_9721] ; UDS=urine drug screen ; 
BrAC=breath alcohol concentration ; TLFB=Timeline Follow -back ; CGI=Clinical Global Impression ; C-SSRS=Columbia Suicide Severity 
Rating Scale ; HAM - A=Hamilton Anxiety Rating Scale ; HAM - D=Hamilton Depression Rating Scal e; POSS=Passero Opi[INVESTIGATOR_224442] ; MINI=Mini International Neuropsychiatric Interview  
 
 
The number prior to X refers to the number of times the procedure is done.  Vital signs are done 1X sitting and 1X standing Pre -dose and 
Post-dose  at each daily dose scheduled. **Lofexidine/Pregabalin Adherence is done by [CONTACT_966]/site collection of bottles per subject an d 
blister packs for all doses. † Day 9 is used for retests if needed, but all assessments are again done as per day 8 unless otherwise noted.  
 
Illicit non -study concomitant meds are covered in TLFB; UDS, Fentanyl  and xylazine  test are done at screen, and Day 1 , Day 8, Day 10, Day 15; 
and Early termination . 
 
17  
 
Protocol V9.0                                                                                                                            11/2/[ADDRESS_269880] aspartate aminotransferase  
BUP/NAL  Buprenorphine/naloxone  
CDC  Centers for Disease Control  
CFR Code of Federal Regulation  
CGI Clinical Global Impression – Rater Version  
CK Creatine Kinase  
CMP  Comprehensive Metabolic Panel  
CNS  Central nervous system  
COWS  Clinical Opi[INVESTIGATOR_2433]  
C-SSRS  Columbia -Suicide Severity Rating Scale  
EOS  End of study  
EQ-5D-5L EuroQol 5 -Dimension 5 -Level  
FDA Food and Drug Administration  
GCP  Good Clinical Practice  
HAM -D Hamilton Depression Rating Scale (Ham -D; 
Hamilton, 1960)  
ICF Informed consent form  
ICH International Council for Harmonization  
IEC Independent Ethics Committee  
INR International Normalized Ratio  
IRB Institutional Review Board  
ISI Insomnia Severity Index  
LFX Lofexidine  
MAT  Medication -Assisted Therapy  
MINI  Mini-International Neuropsychiatric Interview 
(M.I.N.I.) For DSM 5 (Sheehan 1998)  
OUD  Opi[INVESTIGATOR_224443] -Induced Sedation Scale (POSS; 
Pasero ,2009)  
QTc QT corrected by [CONTACT_224533] ( QTc = 
QT/RR(1/3) ). 
SAE Serious adverse event  
SOWS -Gossop  Short Opi[INVESTIGATOR_2433] -Gossop 
(Gossop, 1990)  
TLFB  Timeline Follow -Back Interview (TLFB; Sobell & 
Sobell, 1995 ) 
XR-NTX Extended -Release Naltrexone  
18  
 
Protocol V9.0                                                                                                                            11/2/2022  7.0 INTRODUCTION  
 
This document  is a protocol  for a human  research  study.  The study  is to be conducted  according  to 
US and international standards of Good Clinical Practice (FDA Title 21 part 312, International 
Conference on Harmonization guidelines), and applicable government regulations and Institutional 
research  policies  and procedures.  The Principal  Investigator  [INVESTIGATOR_224444]-investigators  as well as the monitor  and the clinical  staff so that each 
clearly understands and accepts the obligations incurred in undertaking this study. The Principal 
Investigator [INVESTIGATOR_224445] -controlled study; the obligation to conduct it in accordance with applicable 
federal and local regulations; obtain informed consent in accordance with 21 CFR Part 50; obtain IRB 
review and approval before the investiga tion may be initiated, and to ensure continuing review of the 
study by [CONTACT_224534] 21 CFR Part  56. 
 
7.1 BACKGROUND  
 
Extended -release injectable naltrexone (XR -NTX; Vivitrol®), an opi[INVESTIGATOR_224446] (OUDs) in 2010. A single 
injection of [ADDRESS_269881] maintenance (e.g. methadone, buprenorphine -naloxone) 
treatments are unavailable or undesirable due to regulatory or logistical constraints, clinical 
considerations, or patient preference.  
 
Initially met with skepticism, antagonist treatment has attracted interest from an increasing 
number of patients. In a recent cohort of 657 community recruited opi[INVESTIGATOR_2480] -using patients, more than 
half, 52.1%, said they would be interested in trying antagonist  treatment and possibly extended -
release naltrexone (XR -NTX) (Ahamad et al., 2015).  The authors cited daily heroin injection 
(AOR = 1.53; 95% CI = 1.02 –2.31) as positively associated with this decision. Satisfaction with 
agonist treatment and chronic pain  were the most common reasons for unwillingness to take XR - 
NTX. A related study assessed 372 opi[INVESTIGATOR_224447] -assisted therapy (MAT). Among the 
[ADDRESS_269882], 64 (18.5%) preferred methadone, 98 (28%) buprenorphine, 104 (30%) 
XR-NTX, and 80 (23%) preferred “NO MAT” at all, due mostly to negative beliefs about all MATs 
(Uebelacker et al,  2016).  
 
Two recent studies found that XR -NTX treatment was similar in effectiveness to sublingual 
buprenorphine (BUP/NAL). One study, done in the U.S., compared XR -NTX to BUP/NAL in 570 
patients with OUD over 6 months. Though 22% fewer patients started XR -NTX than  started 
BUP/NAL, mainly due to failure to complete detoxification, there was no difference between groups in 
the percent of subjects who relapsed to opi[INVESTIGATOR_2438], number of opi[INVESTIGATOR_224448], or number of 
opi[INVESTIGATOR_224449] d either medication (Lee et al., 2018). In a [ADDRESS_269883], 159 OUD subjects were randomly assigned to XR -NTX or BUP/NAL, 61% 
completed the trial with no significant differences between groups in retention or percent opi[INVESTIGATOR_224450] (Tanum 2017). A third trial randomized 308 probationers or paroled adult criminal 
justice offenders with OUD to either a 24 -week course of XR -NTX (n=153); or 24 weeks of treatment - 
as-usual (n=155) consisting of brief counseling and referrals for commu nity treatment programs. At 6 
months, XR -NTX patients had a longer time to relapse, lower relapse rate, higher rate of opi[INVESTIGATOR_2480] - 
negative urine samples, and no overdoses compared to subjects in the treatment -as-usual group 
(Lee et al., 2016). Results showing  positive effects of extended -release naltrexone were also found in 
Russian studies when comparing opi[INVESTIGATOR_224451]. Petersburg (Krupi[INVESTIGATOR_9729], 2011; 2012;  2019).  
19  
 
Protocol V9.0                                                                                                                            11/2/2022  7.1.2  Detoxification and Transition to XR -NTX: Although the findings  cited above  
suggest patient interest in XR - NTX and its possible effectiveness in reducing time to relapse and 
increasing higher rates of opi[INVESTIGATOR_224452],  methods to  increas e 
the proportion who complete detoxification and transition from opi[INVESTIGATOR_224453].  
 
The usual protocol for opi[INVESTIGATOR_224454], or 
suppressing autonomic over activity with an alpha [ADDRESS_269884], such as clonidine or 
Lofexidine (LFX). The use of αlpha -2 agonists as adjuncts gained popularity when early studies found 
that withholding a single dose of clonidine prior to anesthesia caused a patient to experience an acute 
hypertensive crisis (Brodsky and Bravo, 1976) and it was theorized that α -[ADDRESS_269885] o n the achiness, insomnia, dysphoria and other  subjective symptoms.  
 
Opi[INVESTIGATOR_224455] 2 adrenergic agonists, but patients interested in XR -NTX treatment need a 7 -14-day opi[INVESTIGATOR_2480] -free 
interval to avoid having naltrexone precipi[INVESTIGATOR_224456], thus leaving time to relapse. Clonidine 
avoids this problem (Gold et al, 1980) but does not have FDA approval for this indication, does not 
decrease the dysphoria and o ther withdrawal -related subjective effects, and is unpopular with 
patients and physicians  alike. Studies by [CONTACT_224535] (2005) are an example. They show that only 61% 
of inpatients randomized to clonidine detoxification remained in treatment and had opi[INVESTIGATOR_224457] 13, vs 77% in a buprenorphine detoxified group. Results were even worse in outpatient 
settings where only 5% of clonidine treated patients completed detoxification vs. 29% of those  treated 
with buprenorphine only.  
 
7.1.[ADDRESS_269886] to 
transition to naltrexone and the results were positive in an early study where  56% in the experimental 
group transitioned to XR -NTX vs 33% in the buprenorphine group (Sullivan et al, 2017). However, a 
larger trial of 378 patients randomized to one of three regimens: NTX + BUP; NTX + placebo BUP 
(PBO -B); placebo NTX (PBO -N) + PBO -B found no diffe rence in transition to XR -NTX across groups 
(41-46%), although for those inducted onto XR -NTX, the management of opi[INVESTIGATOR_224458] -NTX was achieved in a structured outpatient setting using a well -tolerated, fixed - 
dose ancilla ry medication regimen common to all three groups. (Bisaga et al,  2018).  
7.1.4  Detoxification  with Pregabalin . During the time that  PGB was available without a 
prescription in Russia, clinicians observed that opi[INVESTIGATOR_224459].  These observations led to a study in which 34 heroin -
addicted patients were randomized to detoxification protocols using PGB alone, or clonidine alone 
(Krupi[INVESTIGATOR_9729], 2017). While  groups did not differ on baseline clinical or demographic features, 15 of 
the 19 PGB subjects com pleted treatment (79%) compared to 7 of 15 (47%) in the clonidine group (p 
= 0.05, Fisher exact test), and a Kaplan -Meier Survival Analysis confirmed better retention in the PGB 
group (p = .001). There was no significant group difference in reduced severit y of withdrawal, however 
the pregabalin group reported less opi[INVESTIGATOR_2506] (p= .05), less anxiety (p=0.05), less depression 
(p=0.05), and higher assessments of general health (p < 0.05). Ketorolac was available as needed for 
pain, and the average dose of s ymptom -triggered ketorolac in the clonidine group was almost twice 
that of the PGB group (60.5 ± 8.2mg vs. 36 ± 7.8mg, (p< 0.05). In addition, the PGB group reported 
less fatigue compared to the clonidine group (16% vs. 47%, p < 0.05) and there was no sign ificant 
difference in AR’s between groups. These findings were consistent with studies using rodent models 
that demonstrated PGB attenuates opi[INVESTIGATOR_43351] (Vashchinkina et al 2017) .
20  
 
Protocol V9.0                                                                                                                            11/2/2022  PGB has a different mechanism of action than alpha -adrenergic receptor agonists as it 
potentiates glutamic acid decarboxylase, an enzyme that catalyzes decarboxylation thus increasing 
the synthesis of GABA, and inhibits calcium influx and release of excitatory  neurotransmitters through 
action at the alpha -2-delta subunit of the NMDA receptor (Kämmerer et al, 2012; Freynhagen et al, 
2016). It is rapi[INVESTIGATOR_24584], reaching a maximum concentration in 10.5 hours that lasts for 8 hours  
and is excreted by [CONTACT_224536], thus unlikely to alter the metabolism 
of other drugs.  It is approved for neuropathic pain, fibromyalgia, adjunctive therapy for adults with 
partial onset seizures and, in Europe, for anxiety (Gajra j, 2007). Side effects occurring in >5% of 
patients are dizziness, somnolence, dry mouth, edema, blurred vision, weight gain and difficulty 
concentrating. It can increase the PR interval (http://labeling.pfizer.com/showlabeling.aspx?id=561),  
but only by 3 -6 msec and at doses of >300 mg/day. It has a relatively low abuse potential  (Schedule  
V) and available without a prescription in Russia until October 2015 when its status was changed to 
the equivalent of U.S. Schedule V due to reports of self -administration to experience opi[INVESTIGATOR_2480] -like 
effects or reduce opi[INVESTIGATOR_43351] (Evoy et al, 2017).  
 
7.1.[ADDRESS_269887]. Unlike clonidine, it has reduced potency at the 
A subtype of the alpha 2 receptor and is associated with less bradycardia and hypotension (Yu et al, 
2008; Gowing et al, 2016). Though its effects are similar to clon idine, its better safety profile is an 
advantage, especially in outpatient settings where hypotension can be a problem (Kahn et al, 1997; Lin 
et al, 1997;  Carnwarth & Hardman, 1998). Like clonidine, it does not target the withdrawal - related 
subjective effects, thus potentiating a greater likelihood for dropout. An inpatient study randomized 
OUD inpatients to detoxification using lofexidine or diazepam. Twe nty-seven percent (15/55) of the 
diazepam patients completed 10 days of treatment, vs 46.4% (26/56) of the lofexidine patients , thus 
more effective than diazepam  although with much room for improvement (Guo et al, 2018). In a pi[INVESTIGATOR_224460] a pproval, lofexidine showed a small reduction in subjective effects compared to 
placebo (a 2 -point difference on the SOWS -Gossop scale) with significantly greater rates of 
detoxification completion (41% vs 28%; Fishman et al 2018). Again, showing the need f or 
improvement, particularly  for patients  transitioning to antagonist  therapy.  
 
7.1.[ADDRESS_269888] 
treatment is unavailable or difficult to access, and reduce overdose risk for those who make the 
transition.  This study, will attempt to identify a PGB /LFX combination that reduces withdrawal - related 
subjective effects without generating more SAE’s  than LFX, as a precursor to a larger  trial. The 
combination of PGB and LFX may result in increased d rowsiness, lightheadedness and trouble 
concentrating.  
 
This study is a phase II, double -blind placebo -controlled, study to examine whether: 1) PGB can be 
combined with LFX and reduce opi[INVESTIGATOR_43351] -related subjective effects; and, 2) if safe and 
effective, can the combination increase the proportion of OUD subjects who transition to XR -NTX. To 
investigate these objectives, preliminary data on the safety and tolerability of PGB/LFX dose 
sequencing, and the reduction of opi[INVESTIGATOR_43351] -related subjective effects , will be obtained in the 
current trial. We wil l use a two -arm comparison; PGB/LFX versus LFX/ PGB -PLA. If the current trial 
shows that a PGB/LFX combination is likely to be  safe effective , and reduces opi[INVESTIGATOR_224461], we will conduct a second trial in which we will test the PGB/LFX 
combination in a larger sample, under well - powered conditions, to evaluate the results of the current 
trial in relation to the effic acy of the combination to reduce opi[INVESTIGATOR_43351] -related subjective effects 
and possibly increase the proportion  of patients who complete detoxification and transition to XR - 
NTX treatment . The first 2-year component will utilize three sites with inpatient units. Each site will 
recruit around 30 randomized  subjects for a total sample size of 90  using DSM -5 criteria  to establish 
21  
 
Protocol V9.0                                                                                                                            11/2/[ADDRESS_269889] phases (see 4.0: Figure 1 schematic): 1) Screening (up to 30 days before inpatient 
admission and randomization) . Patients who were never randomized and who come back after [ADDRESS_269890] be 
reevaluated and assigned a new screening number ; 2) Inpatient Detox (1 – 7) days for medication induction and 
other assessments,  3) Inpatient administration of XR -NTX (Day 8); and, 4) Outpatient Follow -Up (Day 10 and 
Day 15). Dosing for lofexidine and pregabalin will begin at 12:00 on day 1 and be tapered starting at day five. 
This plan will permit dose adjustments for adverse effe cts, such as BP <90 mmHg systolic or <60 mmHg 
diastolic, a clinically significant drop in standing vs sitt ing blood pressure, bradycardia < 50 bpm, or excessive 
sedation. Subjects that need a procedure repeated can continue inpatient treatment through day 9. The Study 
Schema is seen above in 4.0, Figure 1: Overview of Study Schematics Pregabalin (LYRICA®) plus Lofexidine 
(LUCEMYRATM)”. Study assessments are seen in 5.0 Table 1.  
 
 
7.2 INVESTIGATIONAL  AGENT  
7.2.1  Pregabalin Structure (LYRICA®):  described chemically as ( S)-3-
(aminomethyl) -5- methylhexanoic acid. The molecular formula is 
C8H17NO 2 and the molecular weight is 159.23. The  chemical 
structure  is: 
 
Figure 2. Molecular Structure of Pregabalin  
 
 
It is a white to off -white, crystalline solid with a pK a1 of 4.2 and a pK a2 of 10.6 that is freely 
soluble in water as well as in basic and acidic aqueous solutions. The log of the partition coefficient 
(n-octanol/0.05M phosphate buffer) at pH 7.4 is 1.35. LYRICA (pregabalin) is administered orally and 
supplied as hard gelatin capsules . The study is using the  25 mg strength in green capsules, and 10 0 
mg strength in blue capsules.  The capsule shells contain gelatin and titanium dioxide as well as red 
iron oxide .  The imprinting ink contains shellac, black iron oxide, propylene glycol, and potassium 
hydroxide.  
 
7.2.2  Mechanism of Action . Pregabalin (LYRICA ®) binds with high affinity to the 
alpha 2- delta site (a subunit of voltage -gated calcium channels) in central nervous system tissues. 
Although its mechanism of action has not been fully elucidated, results with genetically modified 
mice and compounds structurally related to pregabalin (such as ga bapentin) suggest that binding to 
the alpha 2-delta subunit may be involved in its anti -nociceptive and antiseizure effects in animals. In  
animal models of nerve damage, pregabalin has been shown to reduce calcium - dependent release  
of pro -nociceptive neuro transmitters in the spi[INVESTIGATOR_1831], possibly by [CONTACT_224537] 2-delta containing  
calcium channel trafficking and/or reducing calcium currents. Evidence from other animal models of 
nerve damage and persistent pain suggest the anti -nociceptive activities of pregabalin may also be 
mediated through interactions with descending noradrenergi c and serotonergic pathways originating 
from the brainstem that modulate pain transmission in the spi[INVESTIGATOR_127102].  
 
While pregabalin is a derivative of the inhibitory neurotransmitter gamma• aminobutyric acid 
(GABA), it does not bind directly to GABA A, GABA B, or benzodiazepi[INVESTIGATOR_224462]  

22  
 
Protocol V9.0                                                                                                                            11/2/[ADDRESS_269891] 
acute effects on GABA uptake or degradation. However, in cultured neurons prolonged application of 
pregabalin increases the density of GABA transporter protein and increases the rate of functional 
GABA transport. Pregabalin does not block sodium channels, is not active at opi[INVESTIGATOR_224463], and 
does not alter cyclooxygenase enzyme activity. It is inactive at serotonin and dopamine receptors and 
does not inhibit d opamine, serotonin, or noradrenaline reuptake.  
 
7.2.3  Pharmacokinetics . PGB  is well absorbed after oral administration, eliminated 
largely by [CONTACT_13624], and has an elimination half -life of about 6  hours.  
 
7.2.4  Absorption and Distribution . Following oral administration of  PGB  under fasting 
conditions, peak plasma concentrations occur within 1.5 hours and oral bioavailability is ≥90% and 
independent of dose. Following single (25 to 300 mg) and multiple -dose (75 to 900 mg/day)  
administration, maximum plasma concentrations (C max) and area under the plasma concentration -time 
curve  (AUC)  values  increase  linearly.  Following  repeated  administration,  steady  state  is achieved  within 
24 to 48  hours.  
 
The rate of PGB absorption  is decreased  when  given  with food,  resulting  in a decrease  in Cmax 
of approximately 25% to 30% and an increase in T max to approximately [ADDRESS_269892] on its total absorption  of PGB and therefore can be 
taken with or without food. PGB  does not bind to plasma proteins. The apparent volume of distribution 
of PGB  following oral administration is approximately 0.5 L/kg. PGB  is a substrate for a system that is 
responsible for the transport of large  amino  acids  across  the blood  brain  barrier.  Although  there  are no 
data in humans,  PGB has been shown to cross the blood brain barrier in mice, rats, and monkeys. In 
addition, PGB  has been shown to cross the placenta in rats and is present in the milk of lactating  rats. 
 
7.2.5  Metabolism and Elimination . PGB  undergoes negligible metabolism in humans. 
Following a dose of radiolabeled PGB , approximately 90% of the administered dose was recovered in 
the urine as unchanged PGB . The N -methylated derivative of PGB , the major metabolite of PGB  found 
in urine, accounted for 0.9% of the dose. In preclinical studies, PGB  (S-enantiomer) did not undergo 
racemization to the R -enantiomer in mice, rats, rabbits, or monkeys.  
PGB  is eliminated  from the systemic  circulation  primarily  by [CONTACT_224538] a mean elimination half -life of 6.3 hours in subjects with normal renal function. Mean renal 
clearance was estimated to be 67.0 to 80.9 mL/min in young healthy subjects. Because PGB  is not 
bound to plasma proteins this clearance rate indicates that renal tubular reabsorption is involved.  PGB  
elimination is nearly proportional to creatinine clearance  (CLcr).  
 
7.3 DOSING RATIONALE: RISKS AND  BENEFITS  
7.3.1 Medication  and Blinding  US WorldMeds, LLC (Louisville, KY) will provid e 
lofexidine  (LFX).  Alkermes, Inc. (Waltham, MA) will provide XR - NTX. Each site will have 20 XR -
NTX kits before the study begins to endure immediate availability . The Penn Research Pharmacy will 
prepare blister packs with  each day’s  planed doses in separate a compartment .  Each compartment 
will be labeled with the dosing time on each inpatient study  day.   
Lofexidine will be provided as pi[INVESTIGATOR_8745], 0.18 mg  tablets; pregabalin as blue capsules for the 
100 mg or placebo  doses  and as green capsules for the 25 mg or placebo  doses .  Medical staff will 
be able to reduce or withhold  doses  by [CONTACT_224539] , after receiving  a physician’s order .  Such an order is likely 
to be given  after a clinically significant AE that appear to have been study medication -related .  
Examples  of possible AE’s are: clinically -significant prolongation of the QTc or QRS ; 
clinically significant (>20 mm) drop in blood pressure  (BP) compared to the last reading ; and/or drop 
in systolic  BP of 20 mm or more standing,  or 10 mm or more sitting  to make it ; excessive sedation or 
dizziness  (can use manual blood pressure check if considered necessary) .  Subjects must exhibit 
mild to moderate opi[INVESTIGATOR_224464] (COWS >/= 6, 
23  
 
Protocol V9.0                                                                                                                            11/2/2022  SOWS >/= 4), and pass a naloxone challenge to show they are  free of physiologic opi[INVESTIGATOR_224465] -NTX.  
 
7.3.2  DOSING  SCHEDULES  
 
Table 2: LFX Dosing: all tablets are 0.18 mg  
 
 Time  Day 1  Day 2  Day 3  Day 4  Day 5  Day 6  Day 7  
All 
Groups  0800  0.00 0.54 0.54 0.54 0.54 0.36 0.18 
 1200  0.54 0.54 0.54 0.54 0.36 0.18 0.18 
 1600  0.54 0.54 0.54 0.54 0.36 0.18 0.18 
 2000  0.54 0.54 0.54 0.54 0.36 0.18 0.18 
 Total  1.62 2.16 2.16 2.16 1.62 0.90 0.72 
 
 
                     Table 3: PGB and PGB -PLA Dosing (in mg)  
 
 Time  Day 1  Day 2  Day 3  Day 4  Day 5  Day 6  Day 7  
Group 1  0800  0 200 200 200 100 50 25 
(PGB)  1200  100 100 100 100 75 25 25 
 1600  100 100 100 100 75 25 25 
 2000  200 200 200 200 150 100 25 
 Total  400 600 600 600 400 200 100 
Group 2  0800  0 PLAC  PLAC  PLAC  PLAC  PLAC  PLAC  
(PGB -PLA)  1200  PLAC  PLAC  PLAC  PLAC  PLAC  PLAC  PLAC  
 1600  PLAC  PLAC  PLAC  PLAC  PLAC  PLAC  PLAC  
 2000  PLAC  PLAC  PLAC  PLAC  PLAC  PLAC  PLAC  
 Total  0 0 0 0 0 0 0 
 
 
7.3.3  Dosing Guidelines :  
 
As stated below investigators may choose to stop or reduce the dose of either Study Medication 
although BP and pulse changes are more likely to be due to lofexidine and sedation due to pregabalin.  
 
- Patients can be started and continued on Study Medication  if the pulse is 50 or above.  Medication 
should be held if the pulse is <50 . 
- Patients can be started on Study Medications on Day 1 if COWS >/=6 and SOWS  >/= 4 
- A study physician is required to hold the dose of Study Medication  if the systolic BP is < 90 and/or the 
diastolic is <60.  Investigators should hold  both lofexidine and pregabalin until the next dosing time 
when they can be restarted if the vitals return to 90/[ADDRESS_269893] of lofexidine; sedation, dizziness, or light -headedness are  
potential side effect of pregab alin. A drop of 20 mm or more systolic and/or 10 mm or more diastolic; 
or significant lightheadedness or dizziness, are grounds for holding or reducing a dose of the 
medication that is the most likely cause.  Investigators should use their judgement on which Study 
Medication to hold or  reduce and by [CONTACT_42621].  
 
  7.3.3 .1 The following procedures will minimize risks associated with transient vs. persistent BP 
changes:   
-  If the BP reading shows a pre -medication sitting and/or standing drop  (orthostatic change)  of 
more than 20mm systolic, and/or more than 10 mm diastolic, wait 2 -3 minutes and repeat the 
sitting and standing BP.  
24  
 
Protocol V9.0                                                                                                                            11/2/[ADDRESS_269894] , the physician has the discretion to give full 
dose, reduced dose, or hold the dose of study medication  until the next scheduled dosing time.  
 
Dosing should be given per the protocol scheduled times of 8:00, 12:00, 16:00, and 20:00. However, when 
dosing cannot be given at the protocol scheduled times, Study Medication  can be given up to [ADDRESS_269895] the scheduled dose time. On day 1, if dosing cannot be given at the 12:00  scheduled time, after 2 hours , 
wait until the next sche duled 16:00 dose . In case of scheduled dosing changes, medication cannot be 
scheduled less than a minimum of 3 hours apart.  
7.3.4 Potential Risks:  These include AEs to PGB, LFX, and XR -NTX (for those who transition to 
it); potential adverse interactions between PGB and LFX; and a small risk from venipuncture. Clinical trials are 
conducted under widely varying conditions thus adverse reaction  rates  in clinical  trials  cannot  be directly  
compared  to rates  in clinical  trials  of another similarly -acting drug, and may not reflect the rates observed in 
clinical  practice.  
 
7.3.5  PGB  associated AE’s:  In controlled and uncontrolled trials across various patient populations 
during premarketing development more than 10,000 patients received PGB; approximately 5000 for 6 months 
or more; over 3100 for 1 year or more; and over [ADDRESS_269896] common AE’s leading to discontinuation of PGB . In premarketing trials of all 
populations combined, 14% of patients treated with PGB and 7% of patients treated with placebo discontinued 
treatment prematurely due to AEs. AEs most frequently leading to discontinuation were dizziness (4%) and 
somnolence (3%). In the placebo group, 1% of patients w ithdrew due to dizziness and <1% withdrew due to 
somnolence. Other adverse reactions that led to discontinuation more frequently in the PGB group compared to 
placebo were ataxia, confusion, asthenia, thinking abnormal, blurred vision, incoordination, and p eripheral 
edema (1%  each).  
 
7.3.[ADDRESS_269897] common AE’s in all pre -marketing controlled PGB studies . In premarketing 
controlled trials of all populations, dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, and 
"thinking abnormal" (mostly difficulty with concentration/attention) were more commonly reported by [CONTACT_224540] (≥5%, twice the placebo  rate).  
 
7.3.8  AE’s Leading to Discontinuation in controlled PGB trials.  For those of neuropathic pain in 
patients with diabetic neuropathy: 9% of patients treated with PGB and 4% of patients treated with placebo 
discontinued prematurely due to AEs. In the PGB group, the most common reasons for discontinuation were 
dizziness ( 3%) and somnolence (2%). In comparison, <1% of placebo patients withdrew due to dizziness and 
somnolence. Other reasons for discontinuation with greater frequency in the PGB than placebo groups  were 
asthenia, confusion, and peripheral edema. Each led to withdrawal in approximately 1% of patients. Table 4 
lists AEs, regardless of causality, occurring in ≥1% of patients with neuropathic pain associated with diabetic 
neuropathy in the PGB group for  which the incidence was greater than placebo. A majority of PGB patients had 
AEs with a maximum intensity of "mild" or  "moderate”.  
 
 
 
 
 
 
 
 
 
25  
 
Protocol V9.0                                                                                                                            11/2/2022   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 4: AE’S in trials of Neuropathic Pain Associated with 
Diabetic  Neuropathy in at least 1% of pregabalin -treated 
patients  
 
Body system  
- Preferred term  75 
mg/day 
[N=77]  
% 150 
mg/day 
[N=212]  
% 300 
mg/day 
[N=321]  
% 600 
mg/day 
[N=369]  
% All PGB * 
[N=979]  
% Placebo 
[N=459]  
% 
Body as a Whole        
Asthenia  [ADDRESS_269898] pain  4 1 1 2 2 1 
Face edema  0 1 1 2 1 0 
Digestive System        
Dry mouth  3 2 5 7 5 1 
 
Constipation  0 2 4 6 4 2 
Flatulence  3 0 2 3 2 1 
Metabolic and Nutritional  
Peripheral edema  4 6 9 12 9 2 
Weight gain  0 4 4 6 4 0 
Edema  0 2 4 2 2 0 
Hypoglycemia  1 3 2 1 2 1 
Nervous System        
Dizziness  8 9 23 29 21 5 
Somnolence  4 6 13 16 12 3 
Neuropathy  9 2 2 5 4 3 
Ataxia  6 1 2 4 3 1 
Vertigo  1 2 2 4 3 1 
Confusion  0 1 2 3 2 1 
Euphoria  0 0 3 2 2 0 
Incoordination  1 0 2 2 2 0 
Thinking abnormal† 1 0 1 3 2 0 
Tremor  1 1 1 2 1 0 
Abnormal gait  1 0 1 3 1 0 
Amnesia  3 1 0 2 1 0 
Nervousness  0 1 1 1 1 0 
Respi[INVESTIGATOR_224466]  3 0 2 2 2 1 
Special Senses        
Blurry vision‡ 3 1 3 6 4 2 
Abnormal vision  1 0 1 1 1 0 
* PGB: pregabalin  
† Thinking abnormal primarily consists of events related to difficulty with 
concentration/attention but also includes events related to cognition and language problems 
and slowed thinking.  
 
26  
 
Protocol V9.0                                                                                                                            11/2/2022  7.4 LOFEXIDINE  (LFX)  
 
This medication  was recently  approved  by [CONTACT_224541][INVESTIGATOR_224467] U.K. It is well-absorbed  and reaches  a peak  plasma  concentration  3-5 hours 
after a single dose. Administration with food does not alter its pharmacokinetics and about 30% of the 
dose is converted to inactive metabolites during the first pass. Its major metabolites do not influence or 
inhibit CYP450 isoforms except for a slight inhibition of CYP2D6, thus interactions with CYP substrates 
are not expected  to be clinically  significant.  However , we are excluding  strong  or moderate  inhibitors of 
CYP2D6 such as fluoxetine, paroxetine, or mirabegron, bupropi[INVESTIGATOR_2394], quinidine, terbinafine, cimetidine, 
cinacalcet, duloxetine, and fluvoxamine. The major contributor to its metabolism is CYP2D6, though 
CYP1A2 and CYP2C19 may also be involved. T he elimination half -life is about 12 hours. Nearly all of 
the oral dose is absorbed and accumulation can occur for up to 4 days with repeat dosing. Kidneys are 
the primary route of elimination, and unchanged drug accounts for 15 -20% of the  dose.  
 
7.4.1  Safety . Concomitant  use of LFX may reduce  the efficacy  of oral naltrexon e, therefor e 
oral naltrexone cannot be given to patients in this  study.    
7.4.2  Methadone  and LFX both prolong the QT interval;  therefore,  methadone cannot be 
given to patients in this study.  
7.4.[ADDRESS_269899] common AE’s ( >10%) are orthostatic  
hypotension, bradycardia, hypotension, dizziness, somnolence, sedation and dry mouth. LFX can 
prolong the QT interval and potentiates the sedative effect of benzodiazepi[INVESTIGATOR_1651], alcohol and other 
sedating  drugs.  
7.4.[ADDRESS_269900] dose.  Study 
medication  will be withheld if the seated systolic BP is below 90 systolic  or below 60 diastoli c, and/or if 
the pulse is <50 .  A study physician will be contact[CONTACT_224542] 
>20 mm, or >[ADDRESS_269901] reading.  Study medications may also be withheld or  
reduced  if there is  excessive sedation or other clinically significant AE’s that may be caused by [CONTACT_224543].  First degree AV block is common and does not indicat e a serious  problem . Study 
medication should be stopped and the study cardiologist contact[CONTACT_224544] 2nd degree heart block . 
 
           7.5 EXTENDED -RELEASE NALTREXONE  (XR-NTX)  
XR-NTX will be offered to all patients who complete detoxification, usually on day 8. It is  provided in a 
sealed kit and  administered by [CONTACT_224545].   Subcutaneous injection may increase the likelihood of severe injection 
site reactions .  To reduce  the likelihood of this problem, each needle in the XR-NTX kit is customized 
and no other needle should  be used. Needle length may not be adequate in every patient because of 
body habitus and as a result,  each participant  should be assessed prior to injection to assure that 
needle length is adequate. Patients will be educated to report any injection site reaction and bring it to 
the attention of a clinician and research staff. A physician will examine patients exhibiting abscess, 
cellulitis, necrosis, or swelling to determine if referral to a surgeon is warranted.  AEs that have been 
reported in association with XR -NTX treatment are summarized in section 7.5.1 – 7.5.13.  
 
7.5.[ADDRESS_269902] common AEs and were reported in 
50% of the placebo group and 69% of the [ADDRESS_269903] been reported. In some cases, these 
problems  required  surgical  intervention,  including  debridement  of necrotic  tissue,  with some  resulting  in 
significant scarring. The reported cases were possibly due to excess fatty tissue that interfered with 
27  
 
Protocol V9.0                                                                                                                            11/2/2022  injection  into the gluteal  muscle.  These  problems  were  not observed  in the Krupi[INVESTIGATOR_224468] (personal communication, Krupi[INVESTIGATOR_25195], 2011), and not observed in 
the study of XR -NTX for preventing relapse to amphetamine dependence (Runarsdottir et al,  2017).  
 
7.5.[ADDRESS_269904] been opi[INVESTIGATOR_2480] -free for 7 -10 days, and this possibility will be explained to 
study patients . The absence of physiologic dependence will be determined by [CONTACT_224546] a COWS scores less than or equal to 10 prior to and 15 -20 minutes after a naloxone challenge. If clinically  
significant withdrawal develops, a study physician will treat it with one or more non -narcotic “comfort” medications. 
Note: XRNT may be given to patients after a Naloxone challenge in patients about to go AMA from hospi[INVESTIGATOR_224469].  
 
 
7.5.[ADDRESS_269905] -baseline 
assessment, and the GGT in the 380 mg group was lower compared to placebo at weeks 4, 8, 12, and 
20.  In a subset of patients who were drinking heavily throughout the study, or were  obese or taking 
NSAIDs, there was no increase in the frequency of high liver function tests or hepatic -related adverse 
events (Lucey et al,  2008). The Physician’s Desk Reference (PDR) had a “black box” warning about 
XR-NTX and liver damage but removed it in 2013.  
 
7.5.[ADDRESS_269906] been nausea 
(11% placebo group; 33% XR -NTX), and vomiting (6% placebo; 14% XR -NTX).  
 
7.5.6  XR--N T X and Renal Impairment.  A pharmacokinetic analysis indicated that mild 
renal insufficiency (creatinine clearance of 50 -80 mL/min) had little or no influence on XR -NTX 
pharmacokinetics and that no dosage adjustment is necessary.  Pharmacokinetics of XR -NTX have not 
been evaluated in subjects with severe renal insufficiency, thus individuals with severe renal abnormalities 
will not be included in this study.  
 
7.5.7   XR-NTX and Gender.  In a study of healthy subjects (n=18 females; 18 males), 
gender did not influence the pharmacokinetics of XR -NTX.  
 
7.5.[ADDRESS_269907] and assisted ventilation are rea dily available from persons trained in the use of 
anesthetic drugs and management of respi[INVESTIGATOR_2477].  
28  
 
Protocol V9.0                                                                                                                            11/2/2022   
                         7.5.1 0 Depression and Suicidality.  In controlled trials among patients with alcohol 
dependence, AEs of a suici dal nature (ideation, attempts and completed suicides) were infrequent, but 
more common in patients treated with XR-NTX than placebo (1%). In some cases, suicidal thoughts or 
behaviors occurred after study discontinuation but in the context of an epi[INVESTIGATOR_224470]. Two completed suicides occurred in alcohol treatment 
studies, both in patients treated with  XR-NTX, and depression -related events were more common in 
patients treated with XR-NTX than in those on placebo (1%). However, two studies that have 
specifically examined the relationship between depression and  XR-NTX treatment  found that 
depression and anxiety decrease in association with detoxification and naltrexone treatment (Mysels et 
al, 2011 ; Krupi[INVESTIGATOR_9729], 2016)  
 
7.5.11  Naltrexone Contraindications.  Patients should not receive XR -NTX if they are 
taking opi[INVESTIGATOR_2467]; have current opi[INVESTIGATOR_2561]; are in opi[INVESTIGATOR_43351]; failed a naloxone 
challenge or have a positive urine screen for opi[INVESTIGATOR_2438]; exhibited hypersensitivity to naltrexone, PLG, 
carbo xymethylcellulose, or any other components of the diluent; or have acute hepatitis or liver  failure.  
 
7.5.12  Opi[INVESTIGATOR_224471] -NTX Blockade . 
Patients will be told that attempting to overcome the blockade by [CONTACT_224547][INVESTIGATOR_224472].  
 
7.5.13  Eosinophilic Pneumonia . There was one diagnosed, and one suspected case 
of eosinophilic pneumonia in clinical trials. Both required hospi[INVESTIGATOR_224473]. Should a person receiving Vivitrol ® develop dyspnea and hypoxemia this 
diagnosis should be  considered.  
 
7.5.14 Data from the Russian XR -NTX Study of Opi[INVESTIGATOR_224474] : [CONTACT_224610][INVESTIGATOR_224475] -NTX for opi[INVESTIGATOR_2560] (Krupi[INVESTIGATOR_9729], 2011). In that study, 6 of the 126 subjects (4.8%) randomized to 380 mg 
XR-NTX reported injection site pain as compared to  one of 124 subjects (0.8%) assigned to XR -NTX 
placebo. ALT in the 380 mg XR -NTX group increased an average of 6.9 IU/L as compared to an 
increase  of 5.6 IU/L in the XR -NTX placebo group ; AST increased 3.8 IU/L in the XR -NTX 380 mg 
group,  and 6.7 IU/L in the XR -NTX placebo group; 63 of the 126 (50%) subjects in the XR -NTX 380 mg 
group reported an AE as compared to 40 of 124 (32%) in the placebo group. Three patients reported 4 
SAEs in the XR -NTX 380 mg group (AIDS/HIV or infections); and 4 reported 5 SAEs in the placebo 
group (2 infections, 1 psychotic disorder, 1 other drug dependence, 1 peptic ulcer). These data 
suggest that the risks associated with XR -NTX among persons with opi[INVESTIGATOR_224476].  
 
 
8.0 STUDY  OBJECTIVES  
 
8.1  PRIMARY  OBJECTIVES  
 
To determine if PGB can be combined with LFX to reduce opi[INVESTIGATOR_43351] -related 
subjective effects  
 
8.2  SECONDARY  OBJECTIVES  
 
1) To determine if PGB plus LFX will result in more successful opi[INVESTIGATOR_224477] 7 -day regimen/dosing of either 
PBG/LFX or LFX/PGB -PLA without leaving the inpatient unit or otherwise withdrawing from  
29  
 
Protocol V9.0                                                                                                                            11/2/2022  the study; having a SOWS score of less than  6; a COWS score of less than  9; and a urine 
drug screen that is negative for opi[INVESTIGATOR_2438], excluding buprenorphine, and  fentanyl.  
2) To determine whether PGB plus LFX improves rates of completion of detox  and 
receipt of  XR-NTX 
 
8.3 ASSESSMENT TOOLS USED TO ACHIEVE  OBJECTIVES  
 
The assessment tools used to achieve study objectives are in Table 1.  Effectiveness and safety endpoints, 
based on these assessment tools, are defined in Section 9.2 and 9.4.  
 
9.0 STUDY  DESIGN  
This study is a phase II, two -part randomized, double -blind placebo -controlled, study to assess 
the effectiveness of PGB combined with LFX to reduce opi[INVESTIGATOR_43351] - related subjective effects, 
and to examine whether a PGB/LFX combination can increase th e proportion of opi[INVESTIGATOR_224478] (OUD) subjects who transition to antagonist treatment (XR -NTX).  
The study will use three sites, each with inpatient units that provide beds and care from nurses 
that will be trained in study procedures and dosing requirements.  Each site will recruit around [ADDRESS_269908] phases (see Figure 1 schematic): 1) Outpatient 
Screening; 2) Inpatient medi cation induction plus other assessments on Days 1 -7; 3) Inpatient XR -
NTX administration on Day 8 or 9; and 4) Outpatient Follow -Up (5 days). Total days in study is 15 
days plus or minus the time taken to complete the initial outpatient screening assessment s. 
Randomization will occur before inpatient admission.  
 
9.1  GENERAL  DESIGN  
9.1.1   Phase 1: Outpatient Pre -Screening (Up to 30 days before hospi[INVESTIGATOR_105904]) . 
Study inclusion and exclusion criteria will be assessed to make sure the subject meets admission 
requirements. Those who meet requirements will be given information and details of the study 
including the timeline, potential risks and benefits, inpatient re quirements, confidentiality, and told that 
participation is voluntary. They will be asked to read the informed consent and encouraged to ask 
questions, then given a quiz in which they must answer 9 of 10 answers correctly (three retries 
allowed). Potential  subjects will then be asked to sign the informed consent and given a copy.   
-  Once consented, subjects will be screened for up to 30 days to include the following: completion of 
a locator information form, concomitant medications used in the past 30 days, physical, medical 
history, complete blood cell count (CBC) with differential and PLT, INR, CMP with magnesium and 
calcium, urinalysis with reflex microscopy, urine drug screen,  a fentanyl urine test, a xylazine urine 
test,  a urine pregnancy test, ECG, creatine kinase test, an eGFR calculation, a Child -Pugh score 
(liver function), MINI assessment for Opi[INVESTIGATOR_224479] (e.g. withdrawal), 
Insomnia Severity Index (ISI), Clinical Opi[INVESTIGATOR_9721] (COWS), Short Opi[INVESTIGATOR_224480] (SOWS -G), vital signs  (can use manual blood pressure check if considered necessary) ,  
Timeline Follow - back (TLFB), Clinical Global Impression Scale (CGI), Hamilton Depression and 
Anxiety scales (HAM - D, HAM -A), Columbia -Suicide Severity Rating Scale (CSSR -S), an alcohol 
breathalyzer test, hepatitis B and C tests. Those mee ting admission criteria will be asked to report to 
the inpatient unit on Monday through Friday; randomization will occur at hospi[INVESTIGATOR_063]. Each 
collaborating program will enroll around 30 subjects, 20 to receive pregabalin plus lofexidine and 10 to 
receive placebo pregabalin plus lofexidine. The Pharmacy or designated physician or nurse at each 
site will receive pre -packaged blinded medications from PENN IDS. All study staff will be  blinded.  
 
 
30  
 
Protocol V9.0                                                                                                                            11/2/2022   
  9.1.2 Phase  2: Inpatient Detoxification (Days 1 thru 7) . 
 Subjects are admitted to the inpatient unit, randomized to one of the two study medication 
conditions, and will need to demonstrate withdrawal before starting study medications by [CONTACT_7661] 
a COWS >/= 6 and a SOWS >/=  4. LFX and PGB dosing will begin at 12:00 on day 1 and a 
study drug taper will be done from days  5-7. Dose  times follow the schedule outlined above and 
adjustments will be made based on BP changes and/or other AEs.  Administration of LFX will be 
withheld  or reduced  in cases of dizziness or lightheadedness, clinically significant hypotension 
and/or the BP changes described above.  We will explain to participants the importance for 
adequate oral hydration during the consenting process and throughout the detox. Similar 
procedures will be applied to PGB in cases of excessive sedation, dizziness, peripheral edema, 
or other problematic s ide effects that appear related that medication.  
 
Dosing schedules are in Tables 2 and 3. Assessments for Day 1 through 7 include:  
 
1) ECG is obtained before the 12:00 dose of study medications on Day 1 and before the 
08:00 dose of study medications on Day  2-7 
2) VAS is given before the first dose of study medication at 12:00 on Day 1 and before the 
16:[ADDRESS_269909] dose of study 
medications at 08:00 and before the 16:00 dose of study  medications  
3) ISI given before the 12:00 dose of study medications on Day 1, and before the 08:00 
dose of study medications on Days  2-7 
4)    COWS is given around  12:[ADDRESS_269910] dose of study medication; and 
around 16:[ADDRESS_269911] is admitted without 
the requisite withdrawal  (COWS >/= 6 and SOWS >/= 4) , subsequent COWS and 
SOWS can be administered before the first dose of study medication  until dosing 
criteria is met . 
5)    SOWS -G is given around  12:[ADDRESS_269912] dose of study medication; 
and around  16:00 before the next dose of study medication  
6)    POSS is given prior to all doses (08:00, 12:00, 16:00 and 20:00) of study medication  
 7) Sitting and standing blood pressure and pulse are taken prior to each dose of study  
medication and  1 to 2 hours after dosing , (can use manual blood pressure check if 
considered necessary)  
 8)  Weight taken 1x at screen and Day 15 and recorded on the physical form   
 9)   Adverse events/SAEs recorded daily  
10)  Concomitant medication records reviewed and recorded each  day 
11)  C -SSRS is given at the end of each study day  
12)  Comfort medications given on a PRN  schedule  
 
Successful detoxification is defined as (a) not leaving the inpatient unit before day 8;  (b) 
SOWS of 5 or less and COWS of 8 or less; and , (c) urine drug screen negative for opi[INVESTIGATOR_2438], 
excluding buprenorphine, and fentanyl.   
9.1.3 Phase 3: Inpatient XR -NTX Dosing (Day  8 or 9)  
 
On day 8, subjects will be offered an injection of XR -NTX following naloxone challenge starting 
with a split dose an option of 0.[ADDRESS_269913], wait 10 -20 minutes, then 0.6 mg  (0.8 mg  I.M of naloxone total) A n 
injection of Vivitrol is optional, only if the subject is interested in the XR -NTX treatment ), and only if the COWS 
does not rise above 10 (COWS) within 15 -30 minutes after the challenge. Subjects will be offered a second XR -
NTX dose in the outpatient research clinic 4 to 5 weeks after the Day 8/[ADDRESS_269914] been unable to find a community provider.  Subjects who fail the naloxone challenge on Day 8 will 
receive symptomatic treatment, observed until symptoms resolve, and be offered an opportunity for a repeat 
31  
 
Protocol V9.0                                                                                                                            11/2/2022  challenge and injection on day  9. Note:  
Note: XRNT may be given to patients after a Naloxone challenge in Pts about to go AMA from 
hospi[INVESTIGATOR_224481].  
-  
 
The following assessments will be conducted before the XR -NTX injection:  
1) CK test drawn before IM Injection of naloxone (PGB can elevate CK)  
2) Vital Signs (blood pressure sitting)  
3)  Adverse Events Review  
4)  Urine Pregnancy Test  
5)  VAS scale  
6)  ISI 
7)  SOWS -G 
8)  POSS  
9)  UDS  
10) Urine Fentanyl test  
11) urine xylazine test  
12)  COWS  
13) Naloxone Challenge*  
14) Concomitant Medication Review  
15) C-SSRS  
 
ADMINISTRATION OF EXTENDED -RELEASE NALTREXONE  
 
The following assessments will be conducted after the XR -NTX injection:  
 
1) CGI  
2) HAM -A, HAM -D 
3) Inspection of injection site  
4) Comfort medication(s) (PRN)  
  (It is permissible to give comfort medication at visit 8 for Day 8, 9, and at Day 10 for visit 10, 11, 12, 13, 
14 and 15.  No comfort medication will be given by [CONTACT_224548] 15.  Comfort medication needed after Day 
15 will be considered non -study follow -up care. Patients can get comfort med ications even  if they don’t opt for 
XR-NTX) . 
 
* Optional. Subject can opt not to receive this treatment. The Study Physician will discuss with the 
subject other available options. All assessments for Day [ADDRESS_269915] appropriate and 
available treatment. Subjects will be discharged after the XR -NTX injection (or failed challenge) and 
asked to return to the study outpatie nt clinic for their scheduled Day 10, and Day 15 visits according to 
the intent -to-treat design.  
 
9.1.5 Phase 4: Outpatient Follow -up Visit Assessments (Days 10 and  15) 
 
Assessments at Day 10: (NO POSS)  
1) CBC with diff and PLT, chemistry, calcium, UA with reflex microscopy (Magnesium and INR 
32  
 
Protocol V9.0                                                                                                                            11/2/2022  need not be repeated).  
2) Fentanyl test (urine)  
3) Xylazine test (urine)  
4) UDS  
5) ISI 
6) SOWS -Gossop  
7) COWS  
8) Vital signs  
9) Adverse events, concomitant  medications  
10) C-SSRS  
11) Comfort Medication  (PRN)  
 
Assessments at Day 15: (NO POSS)  
 1)    Physical/weight  
 2)    Urine Pregnancy test for  women  
 3)     Fentanyl test (urine)  
 4)     xylazine test (urine)   
 5)  ISI 
6)  SOWS -Gossop   
7)  COWS  
8)  Vital signs  
9)    Adverse events, concomitant  medications  
10)     TLFB  
11) CGI 
12) HAM -D 
13) HAM -A 
14) C-SSRS  
15) Comfort Medication  (PRN)  
16) UDS 
 
9.1.6 Optional Safety Visit and F/U Day 36 Visit for Second XR -NTX Injection)  
               
 Subjects may be asked to come in a fter the last Day [ADDRESS_269916] the F/U Day 36 visit.  This 
safety visit may not be ne eded  for all subjects. The assessments collected will include: CBC, CMP, Ufentanyl, 
Uxylazine, and a urine drug screen. Compensation will be given for travel.  
 
Subjects may be scheduled to receive a second XR -NTX dose in the outpatient research clinic up 
to [ADDRESS_269917] been unable to find a 
community provider.  Subjects who present for day 36 (+/ - 7 days) will undergo the following procedures:  
1. A urine drug screen  
2. Pregnancy test (women)  
3. Naloxone challenge if there is uncertainty about absence of physiologic dependence  
4. XR-NTX injection  
 
9.[ADDRESS_269918] treatment  
33  
 
Protocol V9.0                                                                                                                            11/2/[ADDRESS_269919] has been identified, a 
CRA or another study staff person will screen him/her for admission/exclusion crite ria. For respondents 
that appear eligible and are interested in participating, an appointment will be made to come to the 
research facility and review study procedures, expectations, and other information in more detail.  
The CRA or another study staff person will explain the study and the potential subject will be asked to 
read the study enrollment consent, and encouraged to ask questions about anything that is unclear. 
Subjects still interested in participating will be as ked to take a 10 -item pre -enrollment quiz and correctly 
answer 9 of 10 true/false questions about the study to be eligible to continue (three additional tries 
permitted). A study physician, or other designated clinical staff person will do the medical hist ory and 
physical. A nurse, physician, medical assistant or other designated personnel will draw blood for 
screening labs, arrange for an ECG whose results will be reviewed by [CONTACT_978] [INVESTIGATOR_8921], and if a 
problem is found, will transmit a copy to the Study Cardiologist, and/or the study Medical Monitor 
and/or the Lead Study PI [INVESTIGATOR_224482] a decision is made as to the next step. If Cardiology is used, 
each site should have a decision sent back to the site within [ADDRESS_269920] 
and make an appointment for admission to the collaborating inpatient unit.   
 
 
10.1 INCLUSION  CRITERIA  
 
1. Male and/or female subjects ≥ [ADDRESS_269921] a stable address in the local area; not planning to move; have documents for ID check  
6. Absence of medical or psychiatric conditions that are likely to interfere with study participation  
7. Have a 12 lead ECG demonstrating a QTc ≤450 msec and a QRS interval ≤120 msec. The site PI 
[INVESTIGATOR_224483] a question of QT 
prolongation or other factors (QTc/ Fri uses the Fridericia formula ( QTc = QT/RR(1/3)) .  If consultation 
is needed, the PENN cardiologists and medical monitor should be  contact[INVESTIGATOR_530]  
8.  If female, have a negative pregnancy test and use adequate contraception if of childbearing 
potential  
 
10.2 EXCLUSION  CRITERIA  
 
1. Current psychotic disorder (bipolar I, schizophrenia, major depression with psychotic 
features,) as defined by [CONTACT_224527]  
2. An alcohol, benzodiazepi[INVESTIGATOR_050], or other sedative use disorder with physiological features  that 
require medication for  detoxification  
3.  History of allergy or other serious adverse event due to treatment with pregabalin, XR -NTX, or 
lofexidine  
4. Pending incarceration in the next 30 days  
5. Homicidal or otherwise behaviorally disturbed requiring immediate attention  
6. High risk for suicide as determined by [CONTACT_49419] ‘yes’ to questions 4 and/or 5 on C -SSRS 
at screening  
7. Blood pressure <90 mm Hg (systolic) or <60 mm Hg (diastolic). If this value is out of 
34  
 
Protocol V9.0                                                                                                                            11/2/[ADDRESS_269922] inclusion or exclusion 
on a case -by-case  basis , (can use manual blood pressure check if considered necessary)  
8.   Heart rate and/or pulse<50 bpm at  screening -sitting  
9.   An Estimated Glomerular Filtration Rate eGFR<90  mL/min/1.73m2 
10. A History of, or current Seizure disorder (excluding childhood febrile  seizures)  
11. Inability to read and/or understand English. For example, unable to understand the informed 
consent as demonstrated by [CONTACT_224528] 9/10 questions correctly on the quiz  
12. Pregnant or  breastfeeding  
13. Currently taking sympathomimetic drugs, or a  thiazolidinedione antidiabetic  
14.  An ALT and/or AST test that is >4X the upper limit of  normal  
15. A Child -Pugh score  >[ADDRESS_269923] 30 days  
 
Note:  Subjects who fail screening for other than medical or severe psychiatric reasons  can be reevaluated by 
[CONTACT_224549] a later date.  
 
10.[ADDRESS_269924]  RECRUITMENT AND  SCREENING  
 
10.3.1   Participating Clinics or Data Collection  Centers  
 
1. Penn Presby[CONTACT_224550] 
2. [LOCATION_001] State Psychiatric Institute, Columbia University [LOCATION_001] New  York 
    3. Mountain Manor Treatment Center Baltimore Maryland  
 
Subjects will be recruited from: 1) the community in Philadelphia and other out -patient Clinics in 
Philadelphia, 2) the surrounding communities of the [LOCATION_001] State Psychiatric institute and other 
outpatient clinic, and, 3) the Mountain Manor area and oth er clinics through advertising in local media, 
newspapers, social media, flyers, transit advertising, and word -of-mouth.  
 
 
10.3.2 Study time  Table  
 
Figure 3: Projected Timetable  
 
 
Months 1 -4 
Study Preparation, Final  Staff 
Training,  IRB Approval  
 Months 4 -22 
Participant Recruitment & Data 
Collection  Months 23 -24 
Data Cleaning, Analysis, 
Manuscript Preparation
 
The proposed study will be completed within 2 Years  
 
• Months 1 -4: September 2019 – January  2020 – IND receipt, IRB approval, protocol 
finalization, case report forms finalized, staff hiring and training completed  
• Months 4 -22: January 2020 - July 2021: Recruitment, study 
explained and informed consent obtained outpatient follow -up for 
90 participants.  
• Months 23 -24: August 2021: Final data clean -up to ensure accuracy and  
completeness.  
Final data analysis and progress reports for n=90 cohort.  
 
35  
 
Protocol V9.0                                                                                                                            11/2/2022  
Enrollment Projections  
 
 
 
 
 
 
 
 
 
Expected   
10.3.3 Enrollment  Projections  
 
Figure 4 : Enrollment Projections  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10.4 TARGET POPULATION DISTRIBUTION (GENDER, RACE,  ETC.)  
 
Men and women 18+ years of age. We expect the sample to include 30% women and 30 -40% minorities 
(predominantly African American). Female -focused recruitment strategies include direct appeals to female 
medical specialties such as OB -GYN offices. Children under the age of 18 will not be  included because the 
safety and effectiveness of XR -NTX extended -release naltrexone has not been established in pediatric patients.  
 
 10.5 RECRUITMENT OF FEMALE  SUBJECTS  
 
Lactating or pregnant females are an exclusionary factor for this study. For the purpose of guidance, the 
following methods are considered acceptable mean s of birth control for this study:  
 
1. Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition 
of ovulation (oral, intravaginal;  transdermal)  
2. Progestogen -only hormonal contraception associated with inhibition of ovulation such as Mirena (a 
progesterone -only IUD) or similarly -acting oral, injectable, or implantable medications; an 
intrauterine device (IUD) or hormone -releasing system; bilateral t ubal occlusion  
3. Diaphragm + spermicide; cervical cap; condom; vasectomized partner; sexual  abstinence  
 
During the study and for a week after the subject’s  final study treatment the research staff will  explain 
to the female subject that they will need to take safety measures to prevent pregnancy by [CONTACT_224551] a medically accepted method of birth control such as stated above. Before the study begins, the 
research staff  will be asked which form of birth control the subject is currently  using, or if they have had a 
tubal ligation, bilateral oophorectomy (both ovaries removed), or hysterectomy and thus no longer require 
hormonal or barrier contraceptives to prevent pregnancy.  
 
If during the [ADDRESS_269925] from the 
medication phase of the study, but ask that s he continues to make the 10 and 15 -day follow -up visits.  1.00 
2.00 
3.00 
4.00 
5.00 
6.00 
7.00 
8.00 
9.00 
10.00  
11.00  
12.00  
13.00  
14.00  
15.00  
16.00  
17.00  
18.00  
19.00  
20.00  
21.00  
22.00  
36  
 
Protocol V9.0                                                                                                                            11/2/2022   
10.6 OBTAINING INFORMED  CONSENT  
 
Study procedures will be described by [CONTACT_224552]: Description of 
the study medication and how it is normally used; rationale for why it is being studied for opi[INVESTIGATOR_224484]; need to begin the study in an inpatient settin g; frequency of dosing and length of 
treatment; potential side effects of pregabalin, lofexidine, and XR -NTX; safeguards and emergency 
procedures; and option to receive sustained release injectable naltrexone or be referred to another 
treatment of one’s  choice upon study completion. Collection of lab specimens (number of 
venipunctures and urine specimens required) will be reviewed as will eligibility, number and frequency 
of the research interviews and self -assessments, and payments for participation and co mpletion of 
follow -up assessments.  
 
Subjects will be assured that participation is voluntary, withdrawal from the study will not 
jeopardize future treatment, and that if at any time the research or clinical teams feel subjects need 
another treatment they will be referred to the most available treatment of their choice. All subjects will 
be informed of the potential risks and benefits including medication side effects, and that their 
participation may be discontinued at any time because of serious medication side effects, non -
compliance with t reatment, new information regarding the safety of study medications , or if continued 
participation is considered to endanger the welfare of subjects or others.  
 
At the end of the consent review session, a [ADDRESS_269926] signs the consent. Subjects scoring below 90% correct will receive additional instructions 
regarding the study and consent, and the quiz will be administered until they score at least 9/[ADDRESS_269927] question (3 retries allowed). Participants will be 
given a copy of the consent form with the name [CONTACT_224609]’s Institutional Review Board (IRB) along with a [ADDRESS_269928] is defined as one  for whom written informed consent was obtained, all eligibility criteria are 
met, and he/she has been randomized to receive study medication. Screen failures will be given 
referrals to other available treatments. A list of screen failures, not identified by [CONTACT_224553], will be  maintained according to the reason of failure throughout the study. The study will 
use screening numbers before randomization numbers are assigned.  
 
10.8 EARLY  WITHDRAWAL OF  SUBJECTS  
 
All randomized subjects are included in the intent -to-treat analysis. After day 15, or at 
termination for patients who discontinue the trial prematurely, subjects will be asked to complete 
the following procedures and assessments: phys ical exam, vital signs, weight , adverse events; 
concomitant medications; blood samples for chemistry, CK, CBC with diff and PLT, liver function; 
urinalysis with reflex microscopy, urine drug toxicology screen; a fentanyl urine test, a xylazine 
urine test, a pregnancy test for females; and the Clinical Global Impression. ECG will be obtained 
for early terminators. Subjects will be referred to the most appropriate and available treatment and 
attempts will be made to obtain these data unless the subject requested they not be contact[CONTACT_224554].  
Subjects will be informed at the consent session that medications could be discontinued if (at 
the discretion of the principal investigator [INVESTIGATOR_224485]): 1) Intolerable side effects occur, or 2) 
Extreme lab values with a repeat test occur, or that he /she may be discontinued from the study due to 
37  
 
Protocol V9.0                                                                                                                            11/2/2022  development of psychiatric or medical problems that require a more intensive intervention than 
provided by [CONTACT_1758].  Examples are psychiatric symptoms that require inpatient treatment (suicidal 
ideation, acute psychosis, acute mania); clinical deteriorat ion or a change in status that requires 
admission to an inpatient medical service; or development of behaviors that compromise safety of the 
subject or staff. Referrals for care will be made and reasons for subject discontinuation from the study 
medication  and/or clinical trial will be documented on the End of Study Final Evaluation Form.  
 
10.[ADDRESS_269929]’s phone number will be called 
during screening to make sure it is valid and to make further screening appointments if necessary. 
Subjects who missed an appointment will be re -contact[CONTACT_224555], then by [CONTACT_224556]. Contacts will be attempted at least twice a week 
for a minimum of two weeks, then less frequently by [CONTACT_2319]. Subjects are not considered lost to follow 
up until the study has been completed and the database is ready to be closed. All d ocuments 
regarding phone contacts (attempted and connected) will be noted in a study phone contact [CONTACT_224557]’s study  binder.  
 
10.9.[ADDRESS_269930] of clinics that was given to them at the completion of visits 8 or 
9. Subjects will not be paid for a second injection as it is not a formal study visit.  
 
10.10 . DATA  COLLECTION  
 
10.10.1  Data Handling & Record Keepi[INVESTIGATOR_007] . Data will be entered at each site into a 
REDCap program constructed by [CONTACT_224558].  
 
10.10.2  Source Documents . Source data include all information, original records of 
clinical findings, observations, or other activities in a clinical trial necessary for its reconstruction and 
evaluation. These data are in source documents such as: hospi[INVESTIGATOR_1097], clinic and of fice charts, 
laboratory notes, memoranda, evaluation checklists, pharmacy records, original data in paper form 
to be recorded into the automated REDCAP instruments, copi[INVESTIGATOR_224486], microfiche, photographic negatives, microfilm or 
magnetic media, x -rays, subject files, and records kept at laboratories, or medico -technical 
departments involved in the clinical  trial. 
 
10.10.3  Case Report Forms (CRFs).  As described in the “assessments” section, they 
include all primary data collection instruments and are entered and checked through the Penn data 
management system (REDCap ). This includes all concomitant medications as well as records of 
adverse events. Each site will be responsible for reviewing and maintaining data entry of all case 
report forms into REDCap data system. All adverse events entries and serious adverse event s 
entries must be reviewed by [CONTACT_224559].  If the PI [INVESTIGATOR_224487], the site should contact [CONTACT_7195] ([CONTACT_224611]).  All paper 
sourced assessment documents should be recorded into RE DCAP daily. Where ever possible, 
direct entry into RECAP is requested.  
 
 
 
38  
 
Protocol V9.0                                                                                                                            11/2/2022  10.11  STUDY MEASURES; SEE TABLES 1 FOR SCHEDULES OF  ADMINISTRATION  
 
1. Medical History: Done by [CONTACT_224560]  
2. Physical/Weight: Done at Screen; and at Day 1 5 
3. Pulse and blood pressure: done sitting and standing 1X at screen, done Day 1 
through Day 7 done before receiving Study Medication  and 1 - 2 hours after receiving 
medication, 1X on Day 8, 1X  (sitting only)  on Day 10  (sitting only) , and 1X on Day  15 
4. ECG: 1X at Screen, 1X each day for Day 1 through Day  7 
5.   Complete Blood Count with diff and PLT: Done at Screening and Day  10 
6.   Chemistry and calcium: Done at Screening and at Day 10  or Day 15 if not obtained at 
Day 10   
7.   Magnesium Screening  (magnesium need not be repeated at  EOS)  
8.   Creatine Kinase  at screening and Day 8 , and early termination  
9.   Hepatitis B and C  done  at screening  
10. Urinalysis with reflex microscopy: Done at Screening and Day  [ADDRESS_269931],  done at screen, day 8/9, day 10, 
and day 15.  
12. Urine Fentanyl . Done at Screen , Day 1 , Day 8/9 , Day 10, and Day 15 . 
13. Urine Xylazine .  Done at Screen , Day 1 , Day 8/9, Day 10, and Day [ADDRESS_269932] : Screen and Day 1, Day 8 /9 prior to the XR -NTX injection , and at Day 15  
15. Adverse Events : Collected by [CONTACT_224561], Day 1 through  Day 15  
16. Clinical Global Impression Scale (CGI; Guy, 1976): A brief severity rating of 
overall health at time of interview using a [ADDRESS_269933]. Administered at day 1, day 8, and  EOS  
17. Clinical Opi[INVESTIGATOR_9721] (COWS; Wesson & Ling, 2003): An 11 -item, staff 
administered instrument that measures objective signs of opi[INVESTIGATOR_2533]. Done 1X 
at screen, 2X daily Day 1 through Day 7, 2X (naloxone challenge) on Day 8* 
(optional), and 1X on Day 10, and 1X Day  15 
18. Short Opi[INVESTIGATOR_9721] (SOWS -Gossop; Gossop, 1990): A 10 -item, staff 
administered scale that measures patient’s perceptions of opi[INVESTIGATOR_2533]. Done 
1X at screen; 2X daily Days 1 - Day 7; and 1X on Days 8 , 10, and 15.  
19. CONCOMITANT Medication (CONMEDS): Any prescribed or non -illicit non -Study 
Medication s used 30 days before screening, and on Day 1 through EOS  
20. COMFORT Medication : See prescribed medications given for comfort during Day 1 
through Day 7, AND Days 8, 10, and 15 by [CONTACT_224562]. Only the 
following comfort medications provided by [CONTACT_224563]: ondansetron 4 mg or 8 mg tid  PO PRN for nausea and vomiting,  
trazodone 100 mg HS PRN insomnia, loperamide 2 mg qid PO PRN diarrhea, and 
a non -steroidal such as Ibuprofen 600 mg qid PO PRN for aches and pains or 
acetaminophen 650 mg (2 tablets 325 mg) PO  qid PO PRN,   cyclobenzaprine  5 mg 
tid PO PRN for muscle aches and pains, and hydroxyzine 25 mg qid PO PRN  
anxiety. In cases of QTc prolongation that are not >550ms or judged to require 
39  
 
Protocol V9.0                                                                                                                            11/2/[ADDRESS_269934] be recorded on the comfort  
medication CRF  on whichever day they are used. All comfort meds ingested on 
Day 8  (or Day 9) whether ingested when an inpatient or  outpatient should be 
recorded on the comfort  medication  form for those days .  It is permissible to give 
comfort medication at visit 8 for Day 8, 9, and at Day 10 for visit 10, 11, 12, 13, 14 
and 15. Comfort medications on Day 15 are  counted as what was taken on the 
calendar day of  day 15 . No comfort medication will be given by [CONTACT_224548] 
15. Comfort medications on Day 15 are  counted up to and including what was 
taken at the time of visit on calendar day 15 . Comfort medication needed after Day 
15 will be considered non -study follow -up care.  Patients can get comfort 
medications even if they don’t opt for XR -NTX).  
21. Hamilton Depression Rating Scale (Ham -D; 1960): A 20 -minute, 24 - item, research 
staff- administered instrument. Done 1X at screen, 1X Day 8, and 1X Day 15  
22. Hamilton  Anxiety  Scale  (Hamilton  A; 1959).  A 5-minute,  14-item,  research  staff- 
administered instrument. Done at 1X at screen, 1X Day 8, and 1X Day  15 
23. Insomnia Severity Index (ISI; Bastien, 2001). 7-item, research staff administered  
scale; takes about 3 minutes; 1X at screen, 1X Day 1 through Day 7,  1X day 8, 1X 
Day 10, and 1X Day  15 
24. Mini -International Neuropsychiatric Interview for DSM - 5 (MINI; Sheehan 1998): 
Identifies current and lifetime DSM -5 Axis I major psychiatric disorders. Takes about 
20 minutes; administered by [CONTACT_224564].  
25. Opi[INVESTIGATOR_2445] (VAS; McMillan & Gilmore -Thomas 1996): Self -
administered 100 mm scale. Done 2X daily Day 1 through Day 7, 1X on Day 8  
26. Pasero Opi[INVESTIGATOR_2480] -Induced Sedation Scale (POSS; Pasero, 2009): Brief, study staff 
or designee administered scale. Done 4X daily (before each dose) Da y 1 through 
Day 7, 1X on Day 8  
27. Timeline Follow -Back Interview (TLFB; Sobell & Sobell, 1995 ): A semi -structured staff 
administered interview of self - reported drug use over the past 90 days at screen and 
EOS (2 - weeks).  
28. The Columbia –Suicide Severity Rating Scale (C -SSRS)  is an assessment tool that 
evaluates suicidal ideation and behavior. It is given at screening and every day from Day 
1 through Day  8, and at day 10 and 15.  
 
10.12 SAFETY  ASSESSMENTS  
 
Total number of adverse events leading to medication discontinuation (in judgment of study  
physician), patients reporting at least one adverse event, clinical lab results, ECG, vital signs, weight and 
evidence  of worsening  (by [CONTACT_224565])  will be considered  in assessing  safety.  
 
See Table [ADDRESS_269935] be filed with source documents. Clinically relevant changes that lead to changes in study 
40  
 
Protocol V9.0                                                                                                                            11/2/[ADDRESS_269936]'s condition.  
 
All laboratory tests with values that are judged significantly abnormal during study participation 
should be repeated. If they do not return to normal/baseline within a period of time judged reasonable by 
[CONTACT_737], the likely cause should be identi fied, an AE form completed, and the Sponsor notified.  
 
Table 5. Clinical Laboratory Tests to Be Performed for This Study  
 
CBC  CMP  Urinalysis  
Hemoglobin   Urine Color  
Hematocrit   Appearance  
Red blood cells  Sodium  pH 
Mean corpuscular volume  Potassium  Specific gravity 
(concentration)  
Mean corpuscular hemoglobin  Chloride  Protein  
Mean corpuscular hemoglobin 
concentration  Carbon Dioxide  Glucose  
Red blood cell distribution width  Glucose  Ketones  
White blood cell count  Creatinine  Bilirubin  
White blood cell Differentials:  Albumin (ALB)  leukocyte esterase  
Neutrophils  Total protein  Nitrite  
Lymphocytes  Calcium  Blood  
Monocytes  Phosphorus  Urobilinogen  
Eosinophils    
Basophils  Aspartate aminotransferase 
(AST)   
 Alanine aminotransferase 
(ALT)  UA Microscopy  
  White blood cell count  
Platelet count  Total bilirubin  Red blood cell count  
  Epi[INVESTIGATOR_224488]:  Blood urea nitrogen  Yeast  
INR  Direct Bilirubin  Crystals  
CK  Cast 
Magnesium   Mucous  
HCV Antibody    
HBcAb (core)    
HBsAg (surface antigen)    
HBsAb (surface antibody)    
41  
 
Protocol V9.0                                                                                                                            11/2/[ADDRESS_269937] is 
discontinued from study treatment due to, an AE, he/she will be followed by [CONTACT_224566]. Potential subjects will be excluded if they have a history of a severe 
psychiatric disorder (schizophrenia, bipolar I, depression with suicidal attempts); impairment of  
renal function; severe liver disease; participated in a medication study within the last 30 days; 
have an illness which may require hospi[INVESTIGATOR_16366]; history of allergy or other SAE 
due to treatment with PGB, XR -NTX or LFX, taking sympathomimetic drugs, or a 
thiazolidinedione  antidiabetic; or impending incarceration;. Pregnant females or women who 
refuse to use acceptable forms of birth control will also be excluded.  
. 
10.13.1   Venipuncture.  Venipuncture will be carried out with good aseptic  technique 
by a nurse or physician or qualified designated person.  
 
10.13.2   Risks Associated with Study  Procedures  
• Behavioral Ratings: Risks are minimal and limited to breach of confidentiality or 
becoming anxious or embarrassed by [CONTACT_43396]. Procedures to  protect 
confidentiality and reduce study -related anxieties are described in section  22.0.  
• Potential Benefits: Subjects benefit from close medical and psychiatric attention over 
and above that which they receive in an inpatient  detoxification.  
 
10.13.3   Risk Benefit Ratio : The first step for transitioning from opi[INVESTIGATOR_224489], often using an alpha -adrenergic agonist such as clonidine or 
LFX. However, patients often drop out due to the dysphoria and other uncomfortable subjective 
effects of withdrawal and do not transition to naltrexone. The recent studies summarized above 
provide data to suggest that PGB can reduce these subjective effects, however the  risks and benefits 
of a /LFX combination have not been studied. Both medications are FDA -approved and we have no 
reason to think they cannot be safely used together, but they have not been  tested.  
 
Identifying a dosing combination that improves detoxification success and transition to antagonist 
treatment has the potential to improve the number of patients that benefit from its relapse and 
overdose protection effects. For these reasons, we think that the risk/benefit potential of this dosing 
comb ination is significant in the likely event that it is safe and effective.  
 
10.13.4  Medical Management of Adverse events.  Evaluation and management of AE’s may 
include additional medication, transfer to a medical unit, reduction in study of medication, temporary 
cessation of study drug, or early termination from the trial if  necessary.  
 
11.[ADDRESS_269938]. Lynch will develop a program using computer -generated, randomly permuted blocks within each site  
 
42  
 
Protocol V9.0                                                                                                                            11/2/2022  that are stratified according to male/female. Upon completing screening assessments, research 
staff will request  randomization be performed by [CONTACT_224567]. The patient will be 
sequentially assigned to the next treatment based on male/female status. At all sites, patient 
treatment will correspond to a unique randomization number.  
 
Penn IDS will upload the randomization lists into a Treatment Unmasking Program, per IDS 
SOP -309. Access to this trial within the program will be provided to authorized Penn users. In the 
event of an emergency, unmasking can occur at any time using the sub ject’s assigned randomization 
number. The user will not be unmasked to the treatment of other subjects. For other sites, [CONTACT_115869] 
will give the randomization list to PENN IDS  who will be  responsible for maintaining the 
randomization blind.  
 
11.[ADDRESS_269939] expi[INVESTIGATOR_1659].  Sites will also be 
responsible for the destruction and expi[INVESTIGATOR_224490] (see destruction procedures for XR -
NTX). Accountability, expi[INVESTIGATOR_1516], a nd destruction will be recorded on a XR -NTX accountability log. 
Each site will administer XR -NTX according to the package insert instructions.  
 
11.5 RECEIPT OF  NALOXONE  
 
Subjects will be offered a naloxone challenge on day 8 using 0.8 mg  or 1.0 mg  I.M. If 
the COWS scores do not rise above 10 within 15 -30 minutes, subjects will receive an injection of 
XR-NTX* given by a study nurse (or NP, etc.), physician (or PA, etc.) or other licensed and 
trained health care provider.  Each site will acquire their own supply of naloxone and will be 
responsible for the s torage, accountability, and dispensing throughout the trial. (*Naloxone 
challenge and receipt of XR -NTX is optional. Subject can request guidance on another form of 
treatment).  
43  
 
Protocol V9.0                                                                                                                            11/2/2022   
11.6  PREPARATION AND ADMINISTRATION OF STUDY  DRUG  
 
Study medication will be prepared by [CONTACT_224568][INVESTIGATOR_71972] (phone: (215 -349-8817). It will be sent to the sites and stored and 
dispensed by [CONTACT_224569]/or designated unit  at the three sites.   
 
11.7  COMFORT  MEDICATIONS  
 
In addition to study medications, subjects can receive, as needed, the following “comfort” medications:  
ondansetron 4 mg or 8 mg tidPO  PRN for nausea and vomiting,  trazodone 100 mg HS PRN insomnia, 
loperamide 2 mg qid PO PRN diarrhea, and a non -steroidal such as Ibuprofen 600 mg qid PO PRN for aches and 
pains or acetaminophen 650 mg (2 tablets 325 mg) PO  qid PO PRN,   cyclobenzaprine  5 mg tid PO PRN for 
muscle aches and pains, and hydroxyzine 25 mg qid PO PRN  anxiety. In cases of QTc prolongation that are not 
>550ms or judged to require stoppi[INVESTIGATOR_224491], diphenhydramine 50 mg hs PO PRN  may be used for 
insomnia , and  trimethoben zamide  300 mg qid PO PRN  for nausea.  It is permissible to give comfort medication at 
visit 8 for Day 8, 9, and at Day 10 for visit 10, 11, 12, 13, 14 and 15. No comfort medication will be given by [CONTACT_224570] 15. Comfort medications on Day 15 are  counted up to and including what was taken at the time of 
visit on calendar day 15 . Comfort medication needed after Day 15 will be considered non-study follow -up care . 
Patients can get comfort medications even if they don’t opt for XR -NTX).  
 
 Each site will maintain records on use of these medications on the Comfort Medication Log. Comfort medications 
will be acquired, stored, and dispensed by [CONTACT_25733]’s research pharmacy or designated person. Store according 
to the information found in the p ackage insert.  
 
11.8  PRIOR AND CONCOMITANT  MEDICATIONS  
 
Prior and concomitant medications are defined as any medications taken before enrolling in 
the study that continues into the study and any medication (not comfort medication or study drugs) 
that are prescribed during the study. They are not the study medic ations (those provided in the 
blister packs). They must be recorded on the study concomitant medication form and entered into 
the database. For example, a diuretic for hypertension medication. All field (start date, dose, times 
per day, stop date, etc.) mu st be captured and recorded for the month before the initial screening 
visit through the follow up  assessment.  
 
11.9 RULING OUT CURRENT PHYSIOLOGIC DEPENDENCE BEFORE XR -NTX ADMINISTRATION  
 (NALOXONE CHALLENGE)   
 
The COWS will be performed before  administering XR -NTX, to assess the subject’s signs/symptoms 
of withdrawal . Naloxone administration should start with a split dose of 0.[ADDRESS_269940], wait 10 -20 minutes, then 
0.6 mg  ( 0.8 mg total). Following in the challenge, the patient should be monitored for 15 -30 minutes for the 
appearance of opi[INVESTIGATOR_43351]. The absence of physiologic opi[INVESTIGATOR_224492] < /=10. If clinically significant withdrawal is shown, a study physician will treat it with one or more of 
the approved non -narcotic “comfort” medications.  
 
1. Signs and Symptoms of a positive naloxone challenge might  include:  
 
▪ Objective —tearing, sweating, goose bumps, shakes, vomiting, pupi[INVESTIGATOR_207202], vital sign 
increases  
▪ Subjective —feeling of temperature change, joint and/or muscle pain, bone pain, nausea, 
abdominal crampi[INVESTIGATOR_007], skin  crawling  
 
2. If opi[INVESTIGATOR_224493], symptoms will be apparent within a few 
44  
 
Protocol V9.0                                                                                                                            11/2/[ADDRESS_269941] be observed for 
15-30 minutes  
 
If manifestations of opi[INVESTIGATOR_224494] -NTX; the 
naloxone challenge test may be repeated in 24 hours (inpatient Day 9) in these patients.  
 
If withdrawal symptoms are present, the patient should be treated with withdrawal reducing medication or 
equivalent and observed until symptoms have resolved (about 20 minutes).  
 
If evidence of withdrawal is absent, naltrexone therapy may be initiated. Please note that even minor and/or 
transient GI symptoms following naloxone challenge be considered evidence of withdrawal since patients with 
such symptoms will often develop severe and disturbing GI symptoms if XR -NTX therapy is then initiated.  
 
3. Signs and Symptoms of positive naloxone Challenge might  include:  
 
▪ Objective —tearing, sweating, goose bumps, shakes, vomiting, pupi[INVESTIGATOR_207202], vital sign 
increases  
▪ Subjective —feeling of temperature change, joint and/or muscle pain, bone pain, nausea, 
abdominal crampi[INVESTIGATOR_007], skin  crawling  
 
4. If an opi[INVESTIGATOR_224493], symptoms will be apparent within a 
few minutes and maximal within [ADDRESS_269942], do 
not initiate naltrexone therapy due to potential risk of precipi[INVESTIGATOR_224495]; naloxone challenge test may be repeated in 24 hours (inpatient Day 9) in these patients.  
 
If withdrawal symptoms are present, the patient should be treated with the clinically most appropriate 
withdrawal reducing medication and observed until symptoms have resolved (about 20 minutes).  
 
If evidence of withdrawal is absent, naltrexone therapy may be initiated. Please note that even minor and/or 
transient GI symptoms following naloxone challenge be considered evidence of withdrawal since patients with 
such symptoms will often develop severe  and disturbing GI symptoms if XR -NTX therapy is then initiated.  
 
12.0 RECEIVING, STORAGE, DISPENSING AND RETURN  
 
12.1 RECEIPT OF PGB, LFX, AND XR -NTX 
 
PGB and LFX will be prepared in blister packs and shipped to the research pharmacies or 
designated persons at each treatment site by [CONTACT_224571].  Resupply of packs is requested by [CONTACT_20143]: [EMAIL_4413] . Upon 
receipt of study treatment medication, an inventory is to be completed and a drug receipt log filled out and 
signed by [CONTACT_17247]. It is important that the designated study staff count and 
verify that the shipment contains all i tems noted in the shipment inventory.  Any damaged or unusable 
study drug in a shipment (active drug or comparator) will be documented in the study files. XR -NTX will be 
shipped by [CONTACT_224572]. The sites are responsible for destruction of the study medication 
per the site’s documented procedures and regulations for controlled substances.  
 
12.2 STORAGE OF INVESTIGATIONAL  MEDICATION  
 
Study medication will be sent from the Penn Research Pharmacy to the sites and stored at their research 
45  
 
Protocol V9.0                                                                                                                            11/2/[ADDRESS_269943] be stored at 20°C to 25°C (68°F to 77°F) 
with excursions permitted to 15°C - 30°C (59°F to 86°F).  Each site should maintain temperature records 
throughout the trial and be able to provide them upon request. If sites have a temperature excursion r elating to 
study drugs, please contact [CONTACT_224573] [PHONE_4746].  
 
12.[ADDRESS_269944] from an assigned blister pack according 
to his/her randomization number at the appropriate times by [CONTACT_224574]. Unused study medication will be c ollected per site SOP.  
 
 12.[ADDRESS_269945] 
accountability in Vestigo, an electronic, web -based pharmacy research program. A similar 
inventory reconciliation will be performed at each site. If electronic recording is not used at the 
collaborati ng sites, the research pharmacy or designated person(s) at the site will keep records 
for the reconciliation of administered, spoiled, expi[INVESTIGATOR_5697], and unused drug.  Paper logs must be 
signed and dated and any discrepancies noted will be investigated, resolved, and documented. 
Unused study drug will be destroyed in  a manner consistent with regulations governing Schedule 
V medications. Medication should not be destroyed until the QA monitor has audited the drug 
accountability log.  
 
12.5 DISPENSING XR -NTX  
 
On day 8 or 9, a 380 mg injection of XR -NTX will be administered according to subjects’ 
consent and evidence that detoxification has been successful, by a negative naloxone 
challenge. Dosing will be maintained in a Drug Accountability Log and recorded in RedCap. 
Subjects who are unable to find an outpatient provider will be offered a second dose of XR -NTX 
up to 5 weeks after day 8 or 9 (day 36 + 7 days).  
 
12.6 STUDY DRUG  ACCOUNTABILITY  
 
US WorldMeds LLC will provide LFX and send it to the University of Pennsylvania’s IDS 
pharmacy. Penn IDS will acquire PGB for all sites and the supplies necessary for preparing active and 
placebo blister -packs. Alkermes, INC. will provide XR -NTX and will s end it to each collaborating site. 
Comfort medications and naloxone will be acquired separately by [CONTACT_25733].  
 
 All study drug received, dispensed, administered, and returned will be managed by [CONTACT_224575], and the Penn Investigational Drug Service for the PENN 
site. Medications must be used only as described in the protocol a nd by [CONTACT_224576] 1572. Study staff will retain the original individual blister -cards, 
including those empty, partially empty, or full, as well as used and unused XR -NTX kits.  Unused 
medications will be colle cted and handled as per site SOP.  Disposition of any study drug lost or 
damaged must be documented on the site accountability log or by a report by [CONTACT_159439]. 
Unused or expi[INVESTIGATOR_224496]. After the monitor audit, unused medication can be destroyed according to their usual 
procedures and documented in the regulatory file.  
46  
 
Protocol V9.0                                                                                                                            11/2/[ADDRESS_269946] data screening/cleaning procedures will be applied. These procedures will 
screen the data for data -entry errors, check for outliers, assess the extent and pattern of missing 
data, and check that appropriate assumption s of normality are met whenever necessary.  
 
13.2  SAMPLE SIZE  DETERMINATION  
 
Power Analyses : The primary goal of this study is to determine  if the PBG/LFX combination 
versus LFX/PGB -PLA is safe and effective in OUD individuals, and shows a reduction in opi[INVESTIGATOR_2480] –
related withdrawal effects  greater than lofexidine alone . To assist in this determination, we 
provide power for the primary  comparison of longitudinal subjective withdrawal measures, 
comparing the groups on rate of decrease across days, using a linear group by [CONTACT_224577]. We have o ne primary outcome, so use an alpha level of 
0.05, and we use two - sided tests. 90 subjects, approximately 30 from each of three sites  (MMTC 
and PENN might have more  than 30 ), who will be randomized into two groups, with 30 assigned 
to LFX/PGB -PLA, and 60 to LFX plus a starting daily dose of 400 mg of PGB and increasing to 
600mg PGB on day 2. Assuming an overall dropout rate of 40%, and within -subjects’ correlations 
of 0.5, th e methods of Hedeker et al (Hedeker, Gibbons and Waternaux, 1999) show that this 
provides 80% power for a group by [CONTACT_224578]’s d=0.[ADDRESS_269947] 
deviations between the two groups.  
 
13.3 STATISTICAL  METHODS  
 
13.3.1 Primary Outcome - Reduction in SOWS -Gossop criterion.  The primary outcome will be 
reduction in subjective withdrawal as measured by [CONTACT_224579] - Gossop (scores range from zero to 30). The 
groups will be compared on the 14 repeated SOWS -Gossop responses obtained during the seven -day 
detoxification period, using linear mixed -effects regression models; the SOWS -Gossop total will be regressed on 
a three -level factor for site, and a two -level factor for medication group, with time and group by [CONTACT_224580]. The 
covariance  structure will include a random intercept and  correlated residuals, with a random slope included if 
necessary for fit. Contrasts between the PGB group and the PGB -PLA group will be estimated from the model. 
Exploratory analyses of heterogeneity of dose effects across sites will be performed including  a site by [CONTACT_224581].  
These models will provide valid estimates and tests if any missing data is statistically ignorable (Laird, 
1998). Dropout may be associated with reports of subjective withdrawal, and will be ignorable if available 
subjective scores prior to dropout are pre dictive of dropout. To assess possible effects of non -ignorability on 
inference, we will perform sensitivity analyses using pattern - mixture models and selection models. For pattern 
mixture models, subjects are grouped on the basis of their pattern of miss ing data. Usually, rarely occurring 
patterns are grouped, so as to keep the number of pattern -groups at a manageable level. This groupi[INVESTIGATOR_224497] a 
nominal variable, which is then used as a predictor in the analyses, although a covariate representing 
missi ngness on a continuous scale can also be used. The regression coefficients associated with this variable, 
and its interactions with the other predictors, quantify how response -predictor relationships differ across the 
different patterns of missingness. Ove rall predictor effects may be found by [CONTACT_224582] (Little, 
1993). For longitudinal data, subjects are usually stratified according to the visit after which they dropped out. 
Hedeker and Gibbons (1997), and Hedeker and Rose (2000), apply th ese methods to mixed effects models in 
longitudinal data. Selection models (Little, 1995; Kenward, 1998; Verbeke and Molenberghs, 2000) take a 
different approach, by [CONTACT_224583], and incorporating the predicted probabili ties 
47  
 
Protocol V9.0                                                                                                                            11/2/[ADDRESS_269948] treatment: Our 
completion threshold criterion is based on the study of Fishman et al (2019), where completion of 
detoxification was defined as “proportion of participants completing the study, defined as having 
recei ved at least [ADDRESS_269949] dose.  
 We will define a three -category ordinal response: (1) failure to complete detoxification, (2) 
completion with failure to start antagonist treatment, (3) completion and receipt of antagonist 
treatment. We will compare these groups using ordinal logistic regres sion models, with a three - 
level factor for site, and a two -level factor for medication group, as the explanatory variables.  
13.4 SAFETY  OUTCOMES  
13.4.1  Suicidality . We will compare the groups on presence of active suicidal ideation on the basis 
of the C -SSRS, which will be administered daily. We define Active Suicidal Ideation to be an endorsement of 
either Question 4 (active ideation without plan) or 5 (active ideation with plan). If there is sufficient variability 
in these repeated binary outcomes, we will compare the groups using a mixed effects logistic regression 
model, similar to the linear mixed effects models de scribed above for the primary outcome; if variability is too 
low, we will use a (non -mixed -effects) logistic regression model to compare the groups on proportion of 
participants reporting active ideation at any time in the  period  
13.4.2  Sedation . The POSS will be administered four times a day  on dose days , yielding a set of 
repeated measures on the POSS score for each participant. We will compare the groups on this score,  using 
linear mixed effects models similar to those described above for the primary  outcome.  
13.4.3  Elevated Creatine Kinase . On day 8 of detoxification, participants will be  classified as having 
elevated creatine kinase if their level is more than three times their s creening level. We will compare  groups 
on this response using a logistic regression model with site and group as explanatory  variables.  
13.4.4  Edema . We will compare groups on the proportion of participants whose study medications 
were discontinued due to peripheral edema, using a logistic regression model with site and group as the 
explanatory  variables.  
 
13.5 TOLERABILITY  OUTCOMES  
 
13.5.1  Achiness . The SOWS -Gossop scale will be administered twice a day. Item  10 yields an 
ordinal measure of achiness. We will use mixed effects ordinal logistic regression models, with site and 
group as the main explanatory variables, to compare the groups on their probabilities of the different 
ordinal  levels.  
 
13.5.2  Anxiety . Item 1 of the SOWS -Gossop yields an ordinal measure of anxiety, and  we will 
compare the groups using mixed effects logistic regression models as for the Achiness item  above.  
 
13.5.3  Insomnia . The Insomnia Severity Index will be administered daily during detoxification, 
and yields a total score. We will compare the groups on the score using linear mixed  effects models 
similar to those described for the primary  outcome.  
48  
 
Protocol V9.0                                                                                                                            11/2/[ADDRESS_269950] POPULATION FOR  ANALYSIS  
 
All subjects who are randomized will be analyzed according to the Intent -to-Treat study design.  
 
13.7 ADVERSE EVENT RECORDING AND REDCAP SYSTEM  ENTRY  
 
AE names will be recorded based on the Medical Dictionary for Regulatory Activities (MedDRA) preferred 
terms found in the REDCap Database. Information regarding adverse events (AEs) will be recorded in 
REDCap and on an adverse event log and will include the following:  
• AE Description  
• AE Code  
• Expectedness  
• Date of Onset/ Change in  Severity  
• Continuous or  Intermittent  
• Severity  
• Seriousness  
• Study Drug  Relatedness  
• Action Taken Regarding Study  Drug  
• Other Actions  Taken  
• Outcome  
Coding will be from a list of terms provided to each site formulated using MedDRA medical terminology . 
 
 
13.8 VITAL  SIGNS  
Vital sign data (HR and BP) will be presented as summary statistics of maximum (max) absolute values, 
max change from baseline, and time to max value during the 1 -hour period after each dose of study 
medication. Data will be compared between groups and within groups by [CONTACT_224584]. Effects will be considered statistically significant at a two -sided p <  0.05.  
 
14.0 DATA  MANAGEMENT  
 
14.1  DATA ACQUISITION AND  TRANSMISSION  
 
14.1.1   Data Entry Methods.  This study will use the University of Pennsylvania REDCap  
(Research Electronic Data Capture) data system for data entry capture. REDCap is a widely -used, 
secure web application that can be used to build and manage surveys and databases online. It provides 
audit trails for tracking data manipulation and user acti vity, and provides Data Queries options for 
documenting and controlling the process of resolving data issues using a data resolution workflow  option.  
 
Data will be collected by [CONTACT_224585] a study number to 
identify the participant. A code linking the participant to the study group will be kept confidential in a 
password protected database. The Physician, nurse pract itioner, clinical research coordinator and 
Clinical Research assistants (CRAs) at each site will be responsible for collecting and checking clinical 
data at their site. All data entered will be cross -checked by [CONTACT_224586], the database is complete and accurate, 
and corrections are done according to GCP requirement. Any inconsistencies/deviations will be 
documented and reviewed by [CONTACT_978] [INVESTIGATOR_224498].).  
 
 
 
49  
 
Protocol V9.0                                                                                                                            11/2/2022   
15.0 SAFETY AND ADVERSE  EVENTS  
 
15.1  DEFINITION OF ADVERSE EVENT  (AE)  
 
Any symptom, sign, illness, or experience that develops or worsens during the course of  the 
study. Abnormal results of diagnostic procedures are considered AEs if they result in study 
withdrawal, are associated with a serious adverse event, lead to additional treatment or further 
diagnostic tests, and/or are considered by [CONTACT_1372] . Normal 
withdrawal events are not recorded as AEs  unless extreme or exacerbated . 
 
15.[ADDRESS_269951] scheduled follow -up, the investigator and /or clinical staff will instruct each subject 
to report any subsequent event(s) that the subject or the subject’s physician or treatment staff 
believes might reasonably be related to study participation. The investigator should notify the 
study sponsor of any death or advers e event occurring at any time after a subject has 
discontinued or terminated participation that may reasonably be related to the study. The sponsor 
should also be notified if  the inve stigator becomes aware of the development of cancer or  a 
congenital anomaly in a subsequently conceived offspring of a subject that has participated in the 
study.  Patients who become pregnant during the study should be followed up to determine if there 
was any evidence  of fetal harm or an  abnormality.  
 
15.4  ABNORMAL LABORATORY  VALUES  
A laboratory abnormality should be documented as an AE if any of the following conditions 
are met: 1) A repeat test confirms it; 2) It suggests a previously undetected disease and/or organ 
toxicity; 3) It requires active management; e.g. discontinuation of  medication, more frequent 
follow -up assessments, further diagnostic investigation, etc.  
 
15.5  HOSPI[INVESTIGATOR_55108], PROLONGED HOSPI[INVESTIGATOR_55108] &  SURGERY  
 
Any AE that results in hospi[INVESTIGATOR_224499] a 
SAE unless it involves detoxification for relapse to opi[INVESTIGATOR_224500]. Any condition that requires surgery 
should be documented as an AE or SAE, depending on the need and length of hospi[INVESTIGATOR_059].  
However, neither the condition, hospi[INVESTIGATOR_059], prolonged hospi[INVESTIGATOR_059], nor surgery are 
reported as an AE in the following circumstances:  
• Hospi[INVESTIGATOR_224501] a preexisting  condition.  
• Hospi[INVESTIGATOR_224502].  
• Hospi[INVESTIGATOR_224503] a worsening or increase in the expected 
frequency of  admissions.  
 
 
 
50  
 
Protocol V9.0                                                                                                                            11/2/2022  15.6  RECORDING  AE’s 
 
At each patient contact [CONTACT_224587], as appropriate, by [CONTACT_5148]. Information on AEs will be recorded in a source document 
and the appropriate CRF. The course of each event will be followed until resolution, stabilization, 
or it has been determined that study treatment or participation is not the cause. SAEs that are 
ongoing at the end of the study will be followed up to determine their outcome. Any SAE that 
occurs  after the study and is considered possibly related to it is to be recorded and reported.  
 
15.7  REPORTING  SAE’s 
 
The Penn IRB considers disability, hospi[INVESTIGATOR_318], 
congenital defects, and life -threatening events to be SAEs that must be reported (orally, e -mail, 
fax) to the Penn IRB when they are identified if judged related or poss ibly related to the study, or 
unexpected. In such cases, a report to the Penn IRB and NIDA is to be filed within 5 working 
days. When additional information is available, a follow -up and/or final SAE report is to be filed.  If 
the report is a narrative, the  minimum necessary information at the time of the initial report 
should include: identifier, subject number, description of event, date of onset, current status, if 
study treatment was discontinued, reason why the event was serious, and whether it was rela ted 
to study treatment or procedures. Copi[INVESTIGATOR_224504]. 
 
15.[ADDRESS_269952] be reported to the study sponsor (Penn) by [CONTACT_6791], email 
or telephone within 72 hours of when the event is reported to any of the study staff. A Serious 
Adverse Event (SAE) form must be completed by [CONTACT_224588] e mailed to the 
study sponsor within 72 hours. The investigator will keep a copy of this SAE form on file at the 
study  site. Report serious adverse events by [CONTACT_224589]:  
 
Kyle M. Kampman, M.D. 
[EMAIL_4415]  
(Sponsor)  [PHONE_4747]  beeper  [PHONE_4748] fax  
George E. Woody, M.D. 
[EMAIL_4416]   
[PHONE_760]   
[PHONE_4748] fax  
(Medical Monitor)    
 
At the time of the initial report, the following information should be provided:  
 
• Study  identifier  
• Study  Center  
• Subject  number  
• A description of the  event  
• Date of  onset  • Whether study treatment  was 
discontinued  
• The reason why the event is classified 
as serious  
• Current  status  • Investigator assessment of the 
association between the event and 
study  treatment  
 
Within the following [ADDRESS_269953] provide further information on the serious 
51  
 
Protocol V9.0                                                                                                                            11/2/[ADDRESS_269954] the understanding of the event. Significant new information on ongoing serious adverse 
events should be provided promptly to the study  sponsor.  
 
 
15.9  REPORTING  DEATHS  
 
The Penn IRB requires that investigators report a death within 24 hours  of staff becoming aware 
of it, if it was unexpected or indicates that participants or others are at increased risk of harm. Other 
deaths are to be reported within 72 hours regardless of whether they were related to study 
participation.  
 
15.10   OTHER REPORTABLE  EVENTS  
 
The following are also reportable to the Penn IRB:  
• Any AE that, even without detailed analysis, represents a SAE that is rare 
in the absence of drug exposure (i.e. agranulocytosis, hepatic necrosis, 
Stevens -Johnson  syndrome).  
• Any AE that would cause a change in the product information, protocol or 
informed consent, or  would prompt IRB action to assure protection of human 
subjects.  
• Information that indicates a change to the risks or benefits of the research, in 
terms of severity or frequency as, for example: safety monitoring indicates that a 
side effect is more severe or more  frequent than expected; new information shows 
that an arm of the study is of no therapeutic  value.  
• Change in FDA safety labeling or withdrawal from marketing of a study  medication.  
• Breach of  confidentiality  
• Protocol change that was taken to eliminate an apparent immediate  hazard.  
• The research team cannot resolve a participant complaint indicating unexpected  risks.  
• Protocol violation (an accidental or unintentional deviation from the protocol) 
that in the opi[INVESTIGATOR_224505].  
• Reporting results: After final data are analyzed, the team will prepare reports 
for scientific, peer -reviewed journals describing the clinical outcomes. The  data 
will be made available, after publication, to other scientists who wish to 
perform additional  analyses.  
 
15.11   IRB NOTIFICATION BY  [CONTACT_224590] (including follow -up information) must be submitted to the IRB 
based on the IRBs current AE/SAE reporting requirements and timeline for reporting (e.g. 5 business days).  
Copi[INVESTIGATOR_224506].  
 
15.12   FDA NOTIFICATION BY  [CONTACT_224591] (Penn) shall notify the FDA by [CONTACT_36983] -threatening experience associated with the use of the drug as soon as 
possible based on the FDAs current SAE reporting requirements and timeline for reporting (e.g. no 
later than 7 calendar days from t he sponsor’s original receipt of the information).  
 
52  
 
Protocol V9.0                                                                                                                            11/2/2022  If a previous adverse event not initially deemed reportable is later found to fit the criteria for 
reporting, the study sponsor (Penn) will submit the adverse event in a written report to the FDA as 
soon as possible based on the requirements and timeline ( e.g. but no later than 15 calendar days 
from the time the determination is made).  
 
 
16.0 STUDY MONITORING/AUDITING/AND  INSPECTION  
 
A research monitor will be selected by [CONTACT_224592]. A CV for the monitor will be obtained, updated bi -annually, and 
kept in the regulatory  binder  to document  the monitor’s  qualifications.  Monitors  will meet  with the sponsor 
and review the protocol, CRF and the monitoring checklists that are completed by [CONTACT_49124].  
On-site or remote monitoring will include:  
• compliance with ICH and GCP(R2)  oversight  
• regulatory and protocol  compliance  
• data quality  
• participant  safety  
• source data  verification  
• review and analysis of eligibility  requirements  
• informed consent  procedures  
• adverse events and all associated  documentation  
• review of study drug  administration/treatment  
• regulatory files, protocol departures  reporting  
• pharmacy  records  
• response  assessments  
• data management (data entry timelines for assessments as defined by [CONTACT_93865])  
 
16.[ADDRESS_269955] with co - 
investigators, the monitor, and clinical staff that the research team understands and accepts the 
obligations incurred in the undertaking of this clinical trial.  
The Principal Investigator [INVESTIGATOR_224507] (research nurses and 
study technician) to ensure they understand and accept the following: the nature of the protocol and  the 
requirements for an adequate and well -controlled study; obligation to conduct the investigation in 
accord with 21 CFR Parts 312, 511, 812, 813 and any other applicable regulations; obligation to obtain 
informed consent in accord with 21 CFR Part 50; ob ligation to obtain IRB review and approval of a 
clinical inve stigation before the investigation is initiated and ensure continuing review of the study by 
[CONTACT_224593] 21 CFR Part 56; and keep the sponsor informed of IRB approvals and 
subsequent actions concerning the  study.  
Training will consist of an explanation of the protocol and review of the CRF. In addition, the 
duties of each member of the staff outlined in all applicable regulations will be reviewed. All questions 
will be answered.  
A report of the Study Initiation will be written by [CONTACT_224594], specifically noting 
the information reviewed with the clinical staff and any questions generated during the training. The 
report will be filed in the regulatory binder. A copy of the Study Initiation Report will be sent to the 
Office of Human Research, University of Pennsylvania School of Medicine, Room 150 Anatomy - 
Chemistry Building, Philadelphia, PA  [ZIP_CODE] -6061. 
 
 
53  
 
Protocol V9.0                                                                                                                            11/2/[ADDRESS_269956] Operating Procedure PM 504. Enrollment will be complete when 90 patients are 
randomized into the trial. Approximately 2 patients/site will be randomized pe r month and monitoring 
visits conducted periodically throughout the study. The first visit will occur no more than two weeks 
after the first patient is entered. Subsequent visits will be conducted quarterly, as described below.  
• Visit 1: Initiation Visit  
• Visit 2: Approximately 25% of subjects to be randomized have completed the trial and 100% 
Source Document Verification for the first two randomized  subjects  
• Visit 3: Approximately 50% of subjects to be randomized have completed the  trial. 
• Visit 4: Approximately 100% of subjects to be randomized have completed the trial. This visit 
serves as the closeout -monitoring  visit. 
If a greater than 10% error rate is noted during the data review, the monitor will source data verify 100% of the 
data on a larger sample at the following monitoring visit  
 
16.[ADDRESS_269957] sign and date the monitoring log.  
 
16.4  MONITORING  REPORT  
 
All monitoring visits will be documented on the Monitor’s Report and Visit Checklist. The original 
report for each visit will be filed in the regulatory binder and copi[INVESTIGATOR_224508] (DSMB) and the Office of Human Research at the aforementioned address . 
 
16.5  VISIT 4: CLOSE -OUT  VISIT  
 
Monitoring visits can be documented on the Visit Report form located on the Penn Office of Human 
Research (OHR) website. The monitor and investigator will review the report and file it in the Monitoring 
Binder. In addition to the Monitoring Visit Report, t he monitor will write a letter to the PI [INVESTIGATOR_224509].  
 
 
17.0 MEDICAL MONITORING  
 
17.1 SAFETY AND MEDICAL  MONITORING  
 
The Site Principal Investigator [INVESTIGATOR_224510]/her site. The Study PI 
[INVESTIGATOR_224511]. Safety  monitoring  will include 
assessment and reporting of adverse events as noted above, as well as construction and 
implementation of a site data and safety -monitoring plan (see section 9 Auditing, Monitoring and 
Inspecting). Medical monitoring will include a regular assessmen t of the number and type of serious 
adverse events. The Medical Monitor for this study is [CONTACT_224612].  
 
54  
 
Protocol V9.0                                                                                                                            11/2/2022  18.0 ETHICAL CONSIDERATIONS AND  SAFETY  
 
18.1  GOOD CLINICAL PRACTICE  (GCP)  
 
This study will be conducted according to US and international standards of Good 
Clinical Practice (FDA Title 21 part 312; International Conference on Harmonization guidelines) 
and all applicable governmental regulations and institutional policies and proc edures. The 
protocol and any amendments will be submitted to NIDA, and the Penn IRB for approval before 
procedures are changed unless they require immediate action to protect participants’ safety. All 
subjects will be given a copy of the informed consent d escribing the study with sufficient 
information for them to make an informed decision about participation. Any information obtained 
in connection with the study that can be used to identify participants will be kept confidential. An 
informed consent will b e written and submitted along with the protocol for review by [CONTACT_224595]. No procedures will be done unless the participant has reviewed and 
been given the opportunity to ask questions about the purpose and procedures used in the study 
and understand its risks and benefits. All participants must sign the informed consent in order to 
participate in the  study.  
 
18.[ADDRESS_269958] for further instructions or information. In the event that a 
patient i s hurt or injured as a result of participation in the study, he/she is to contact [CONTACT_224596]. In the event of physical injury resulting from research procedures, treatment will be 
provided without cost to the patient, but f inancial compensation is not otherwise offered from the 
University of Pennsylvania or the participating site. If the patient has an illness or injury that is not directly 
related to study participation, the patient’s insurance or will be responsible for th e cost of medical care.  
 
18.[ADDRESS_269959] in setting up the randomization sequences. The patient will be 
sequentially assigned to the next treatment based on male/female status. At Penn IDS, the treatment will 
correspond to a unique randomization number.  
 
Penn IDS will upload the randomization lists into a Treatment Unmasking Program, per IDS SOP -309. 
Access to this trial within the program will be provided to authorized Penn users. In the event of an emergency, 
unmasking can occur at any time using the subject’s assigned randomization number. The user will not be 
unmasked to the treatment of other subj ects. The subject, or treating physician can call the site PI [INVESTIGATOR_224512] a release of authorization of medical information for the non - 
study treating physician. Study personnel will follow -up with an attempt to secure written authorization from the 
subject, if possible, for the autho rization to release medical information to the stated non -study physician.  
 
19.0 STOPPI[INVESTIGATOR_224513]  
 
19.1  STUDY STOPPI[INVESTIGATOR_224514], 
55  
 
Protocol V9.0                                                                                                                            11/2/[ADDRESS_269960]  access  to unblinded  data in order  to determine  the association  between  adverse  events  and study 
medication. If a pattern of significant adverse events is uncovered that suggests that the risks of 
continuing the trial outweigh the expected benefits of the trial then the DSMB will recommend that the 
study be  stopped.  
 
19.2  MEDICATION DISCONTINUATION  CRITERIA  
 
All randomized subjects are included in the intent -to-treat analysis. All subjects who 
prematurely discontinue treatment will be scheduled for a final evaluation and end -of trial visit (unless 
these two fall within 2 weeks of each other), and the follow up  visit. Subjects are not dropped from all 
study activity unless they request to not be contact[CONTACT_224597].  
 
Subjects will be informed at the consent session that medications may be held or discontinued due to 
intolerable side effects, hypotension or other problematic cardiovascular effects, or extreme lab values 
confirmed by a repeat test. (AST or ALT levels gre ater than 4 times upper limit of normal; elevated BUN, 
creatine kinase, or other evidence of renal damage). Subjects will also be informed at the consent session that 
he or she may be discontinued from study treatment due to: 1) Development or exacerbation  of significant 
psychiatric or medical symptoms which necessitate admission to a medical unit or an intervention different 
from that provided by [CONTACT_760]; 2) Clinical deterioration for any reason or a clinical status which 
necessitates inpatient admiss ion; 3) Prolonged QTc after repeat ECG; 4) Blood pressure is less than 90 mm 
Hg (systolic) or less than 60 mm Hg (diastolic). For sitting to standing blood pressure  (orthostatic change) , if 
there is a change in systolic blood pressure of more than 20mm or diastolic blood pressure more than  10mm  
HG, the dosing nurse or physician may hold the lofexidine or pregabalin dose until the next dose and then 
recheck  (can use manual blood pressure check if considered necessary) . If at any point blood pressure is less 
than 90/[ADDRESS_269961]’s  casebook  
 
20.[ADDRESS_269962] STIPEND AND REIMBURSEMENTS  
 Each site will reimburse subjects as per the procedures below:  
 
TABLE 6: PENN SUBJECT STIPENDS AND REIMBURSEMENTS  
 
Screen  Day1  Day2  Day3  Day4  Day5  Day6  Day7  Day8  Day9  Day10  Day15  
 InPatient  
Admission  InPt InPt InPt InPt InPt InPt InPt 
VIVITROL  InPt 
optional  F/up F/up 
50.00  125 125 125 125 125 125 125 125 125 50 50 
10.00  10.00        10.00*  10.00*  10.[ADDRESS_269963]  as the payment method. The patient’s social security 
number will be collected but not used or stored in any data records kept by [CONTACT_67300] 
56  
 
Protocol V9.0                                                                                                                            11/2/2022  staff. Subjects will receive $50 for completing screening assessments and a maximum of $10.00 
total for travel reimbursemen t for screening . During this inpatient phase of the study, patients will 
be reimbursed $125.00 per day for completing assessment for a possible total of up to $1000.00, 
plus $20.00 for travel on days 1 and 8 (admission and discharge) for a total of $1200. If subjects 
are inpatient for 9 days, however, as seen in Table 8 above, the maximum reimbursement for 
completing all assessments for  screening and the 9 inpatient days will be $1175, plus a total of 
$20.00 for travel reimbursement for Screening on Days 1 and 9 for a maximum total for completing 
all assessments of $1205.00. For the follow -up visits -Day 10 and Day 15, subjects will recei ve 
$50.00 for completing all outpatient assessment for a total of up to $100.00, plus a total of $20.00 
for travel reimbursement for a total of $120.00. The maximum that a subject can receive for 
screening, a 9 -day inpatient stay completing all assessments , plus outpatient visits and travel 
reimbursement is $1325.[ADDRESS_269964] can receive for the 8 -day 
inpatient stay, completing all assessments plus travel reimbursement is $1200.00.  
 
TABLE  7: MOUNTAIN MANOR SITE SUBJECT STIPENDS AND REIMBURSEMENTS  
 
 
 Screen  Day1  
InPt  
Admt  Day
2 
InPt  Day
3 
InPt  Day
4 
InPt  Day
5 
InPt  Day6  
InPt Day7  
InPt Day 
8 
InPt 
VIVITROL  Day 
9 
(Possible)  
InPt 
VIVITROL  Day 
10 
F/up  Day 
15 
F/up  
Assessments 
Total  50 125 125 125 125 125 125 125 125 125 50 50 
Travel  10 10       10* 10* 10* 10* 
Total  60 135 125 125 125 125 125 125 135 135 60 60 
 
This study will use Clinical Trials Payer (CT Payer) gift cards as the method of payment.  
• Subjects will receive $50 for completing assessments during the screening visit.  
• During the inpatient phase of the study, upon completion of all assessments on each inpatient day, 
patients will be compensated $125.00 (Days 1 -8; possibly including day 9).  
 
• For the follow -up visits -Day 10 and Day 15, subjects will receive $50.00 for completing all 
assessments. In addition, subjects will receive $10.00 reimbursement for travel for the screening visit, 
for travel on the day of inpatient admission and discharge* , and travel for the day [ADDRESS_269965] can receive for a 9 -day inpatient stay plus outpatient visits, and 
travel reimbursement is $1325.00. The maximum that a subject can receive for the average 8 -day 
inpatient stay and completing assessments plus travel reimbursement is $1200.00. You will only receive 
reimbursement for travel if you are traveling to or from the treatment center for study related reasons. 
You will receive your CT Payer Card and be reimbursed duri ng screening but will not be reimbursed for 
other study procedures until you are released from inpatient care.  
 
Please note: In order to be compensated for participation in this study, you must provide your Social 
Security Number. Additionally, please note that the University of Pennsylvania is required to report to 
the IRS any cumulative payments for participation in research studies that exceed a total of $600 in a 
calendar year.  
 
 
TABLE 8 : COLUMBIA SITE SUBJECT STIPENDS AND REIMBURSEMENTS  
 
 
Screen  Day1  Day2  Day3  Day4  Day5  Day6  Day7  Day8  Day 9  Day10  Day 15  
 InPt Admt  InPt InPt InPt InPt InPt InPt InPt   optional  OutPt  OutPt  
57  
 
Protocol V9.0                                                                                                                            11/2/2022  VIVITROL  F/up  F/up  
50.00  50.00  50.00  50.00  50.00  50.00  50.00  50.00  50.00  50.00  50.00  50.00  
10.00  10.00            10.00  10.00*   10.00   10.00  
Total             
60.00  60.00  50.00  50.00  50.00  50.00  50.00  50.00  60.00  60.00  60.00  60.00  
 
You will be paid during the study. The study involves time -consuming assessments that are not included 
in usual treatment  and you will be paid for the time and travel needed to complete assessments. You 
will receive $50 for completing assessments during the screening visit. During the inpatient phase of the 
study, upon completion of all assessments on each inpatient day, you  will be compensated $50 for a 
possible total of up to $450 if you are inpatient for 9 days, however as seen above, the expected average 
inpatient stay is 8 days. For the follow -up visits -Day 10 and Day 15, you will receive $50 for completing 
each outpatie nt assessment for a total of up to $100. In addition, you will receive $10 reimbursement for 
travel for the screening visit, travel on inpatient admission day and discharge from inpatient, and $50 for 
the day 10 and day 15 follow -up visits. The maximum tha t you can receive for a 9 day inpatient stay plus 
outpatient visits, and travel reimbursement is $650.00 for the study. The maximum that you can receive 
for the average 8 -day inpatient stay and completing assessments plus travel reimbursement is $600.00.  
 
Please note: In order to be compensated for your participation in this study, you must provide your 
Social Security Number. For compensation of $[ADDRESS_269966] with the “Priv acy Rule” under the Health 
Insurance Portability and Accountability Act (HIPAA) and other applicable laws. All subjects sign a 
HIPAA -authorization form, receive a copy of this form, and receive a notice of the site’s privacy 
practice. HIPAA signed forms ar e retained in locked file cabinets with patients’ source documents.  
 
Information  about  study  subjects  will be kept confidential  and managed  according  to requirements 
of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). Those regulations require 
a signed subject authorization informing the subject of the  following:  
• What protected health information (PHI) will be collected from subjects in this  study  
• Who will have access to that information and  why 
• Who will use or disclose that  information  
58  
 
Protocol V9.0                                                                                                                            11/2/2022  • The rights of a research subject to revoke their authorization for use of their  PHI. 
In the event that  a subject revokes authorization to collect or use PHI, the investigator, by 
[CONTACT_5151], retains the ability to use all information collected prior to the revocation of subject 
authorization. For subjects that have revoked authorization to collect or use P HI, attempts should be 
made  to obtain  permission  to collect  at least  vital status  (i.e. that the subject  is alive)  at the end of their 
scheduled study  period.  
 
No information about subjects will be disclosed to others without the subject’s prior written 
permission, except as stated in the informed consent, or if necessary to protect the rights or welfare 
of a subject in accordance with the law. Names or unique id entifying information are never used in 
the publication of research data. Procedures designed to maintain confidentiality include: (1) formal 
training  for all research  staff on the importance  of confidentiality;  (2) procedures  to protect  a patient’s 
confidentiality; and (3) formal mechanisms limiting access to information that can link data to 
individual patients. Data forms that include identifying information are kept in locked cabinets. Only 
the unique identification (ID) number, assigned  at the time of initial contact [CONTACT_224598], data transfer, analyses, or other file management procedures. To facilitate 
tracking, a password -protected computer file on a secure server is maintained containing the 
identity of pati ents, ID numbers, and information about how they can be reached. This file, however, 
contains no clinical data. All data are stored in a securely locked area accessible only to authorized 
research personnel. The Principal Investigator (PI) is required to a llow trial -related monitoring, 
audits, IRB review, and regulatory inspection by [CONTACT_184081]. The 
FDA, IRB, and other regulatory authorities will also have access to source documents. We inform 
subjects of this access in the informed consent. HIPAA regulations are  followed.  
 
 
23.[ADDRESS_269967]  has been  established  at the Center  for the Studies  of Addiction  with the 
following  purpose  (according  to NIDA  guidelines):  to assure  that the safety  of study  subjects  is protected 
while the scientific goals of the ongoing studies are being met. The DSMB is charged with monitoring  
safety  of participants  and quality  of the data,  as well as the appropriate  termination  of studies when 
significant benefits or risks have been uncovered or a clinical trial cannot be concluded successfully.  
 
23.[ADDRESS_269968]  will meet  every  six months 
(unless more frequent meetings are deemed necessary) and will be chaired by [CONTACT_224599], M.D., a 
faculty member within the Department of Psychiatry at the University of Pennsylvania. Other members 
of the board include faculty of  the University  of Pennsylvania  School  of Medicine,  Department  of 
Psychiatry.   
 
When the current study is reviewed, [CONTACT_224613] will prepare and submit a summary  report 
on the trial  status,  followed by  a closed  session  under  the direction  of Dr. McKay.  Issues  related  to 
recruitment,  subject  safety  and efficacy, whether the primary study question is being answered, 
conflict of interest,  confidentiality,  and ongoing study review (including AEs, SAEs, and regulatory 
issues) will be  assessed. Following  each DSM Board meeting, Dr. McKay  will make recommendations 
to [CONTACT_224613], and a final  report  (edited by  [CONTACT_224600])  will be prepared  and submitted  to 
NIDA,  the Penn  IRB, and (if required)  the FDA. In  addition  to semiannual  reviews,  at the occurrence  of 
59  
 
Protocol V9.0                                                                                                                            11/2/[ADDRESS_269969] fatal medication associated 
adverse event the protocol will be  reviewed by [CONTACT_224601].  
 
24.0 DSMP STUDY MONITORING PLAN  
 
This study has a monitoring plan on file with NIDA. The investigator will allocate adequate 
time for such monitoring activities and also ensure that the monitor or other compliance or quality 
assurance reviewer is given access to all the above noted study -related documents and study 
related facilities (e.g. pharmacy, diagnostic laboratory, etc.), and has adequate space to conduct 
the monitoring visit.  
 
25.0 COVID SAFETY PLAN  
 
a. Risk for COVID Procedures:  
1. COVID PRECAUTIONS – University of Pennsylvania  
  
I. When you bring your study subjects in for their visit to [ADDRESS_269970] within 24 -48 hours is acceptable within the context of your planned study 
admissions.  
IV. Once the patient is admitted, they will be quarantined for 72 hours in a single room, re -
tested, and if negative, will then be released from quarantine into a semi private room.  
 
 
2. COVID PRECAUTIONS – MOUNTAIN MANOR Treatment Center  
 
I. Outpatient Screening  
Standard Covid screening questions and Covid testing will be incorporated into the screening 
visit. Study staff will follow standard infection control procedures including wearing masks 
and distancing, during consent and assessments.  
II. Treatment center admission  
Patients receive Covid screening questions and Covid testing on the day of admission. 
Admitted patients are admitted in cohorts, separated from the general treatment population 
until Covid results are known. Patients who test Covid negative are integrated into the 
general treatment population. Patients who test positive are placed in medical isolation until 
an appropriate disposition can be arranged. Study staff and usual care clinical staff follow 
standard infection control procedures including wearing mas ks, use of other PPE as 
appropriate, and distancing.  
III. Post discharge follow -up 
Any post discharge study assessments may be obtained remotely by [CONTACT_224602].  
 
3. COVID Precautions – Columbia University  
There are risks of exposure to coronavirus 2019 (COVID -19). At this time, there is still a significant 
risk of infection from COVID -19 whenever entering a public setting or interacting with others. 
60  
 
Protocol V9.0                                                                                                                            11/2/[ADDRESS_269971] SOP. Below are additional precautions we are taking due to COVID -19. 
 
I. All research at NYSPI [INVESTIGATOR_224515] -person visits and procedures.  
- We now use technology (telephone and computer) to perform all possible research 
procedures (such as obtaining consent, clinical interviews, symptom scales, and other 
tests) remotely.  
- We are recommending that only tests and procedures that cannot be performed remotely 
should take place in -person. If the participant prefer s an in -person meeting for a specific 
visit or procedure, we encourage him/her  to discuss this possibility with the study team.  
II. We are monitoring research participants and staff for signs and symptoms of COVID -
19. 
- The participant  will be contact[CONTACT_224603] -19. Upon their arrival to NYSPI, 
we will again ask the participant  questions about any possible COVID -[ADDRESS_269972].  
III. We are taking extra precautions at NYSPI [INVESTIGATOR_224516] -19 infection.  
- When the participant  enter s NYSPI, he/she  will be  required to wear a face covering. If they 
do not have one, they will be given a surgical face mask.  
- Staff will wear masks and other personal protective equipment as appropriate to the 
procedure (e.g., gowns, gloves).  
- The participant  will be asked to maintain physical distancing (at least 6 feet space between 
them  and other people) while at NYSPI [INVESTIGATOR_224517].  
- Alcohol -based hand sanitizer will be provided at the building entrance and many other 
areas.  
- We are restricting visitor access to only those who are essential for our participants’ care.  
- Visitors will be screened for fever and symptoms of COVID -[ADDRESS_269973] research participants and staff from COVID -19 at NYSPI.  
- All equipment used by [CONTACT_4317] (e.g., blood pressure cuffs, EKG machine) will continue 
to be thoroughly disinfected before and after each participant’s use.  
V. Procedures for admission to the inpatient unit:  
- All participant must present to the unit with evidence of a negative COVID test. On the day 
of admission the participant will be brought directly to the back of the dorm area. The 
participant must be wearing a mask and will be assigned to a single room. Th e participant 
will remain in this room for at least the first [ADDRESS_269974] their telephone during that time so they can call family/friends and play games. Of 
note, the telephone will not be available after the first [ADDRESS_269975] 24 hours staff will provi de a new mask to them daily which they are encouraged to 
wear at all times while in public places.  
- Upon admission, the unit staff will send off a COVID nasal swab to [LOCATION_001] Presby[CONTACT_224604]. Once that returns negative and 24 hours has elapsed the participant can enter 
61  
 
Protocol V9.0                                                                                                                            11/2/[ADDRESS_269976] is positive 1) research procedures will be halted, and 2) a 
clinical decision involving the Clinical Director will be made regarding appropriate next 
steps.  
 The participant will be made aware that they will also have a COVID antibody (serum) test 
drawn soon after admission. They will have an additional nasal swab COVID test prior to 
discharge from the unit.  
 
26.0 AUDITING AND INSPECTING  
 
The investigator will permit study -related monitoring, audits, and inspections by [CONTACT_1383]/IRB, 
the sponsor, government regulatory bodies, and University compliance and quality assurance 
groups of all study related documents (e.g. source documents, regulator y documents, data 
collection instruments, study data etc.). The investigator will ensure the capability for inspections of 
applicable study -related facilities (e.g. pharmacy, diagnostic laboratory,  etc.).  Participation as an 
investigator in this study imp lies acceptance of potential inspection by [CONTACT_116631].  
 
27.[ADDRESS_269977] IN THE DSM  
 
All University of Pennsylvania investigators conducting clinical trials are required to submit a Financial 
Disclosure Form. This form is submitted either in connection with submission of a grant application or 
proposal transmittal form to the Office for Re search Services (ORS), or with submission of a protocol to the 
Institutional Review Board (IRB) for approval. The IRB or the ORS review disclosures to determine if it 
appears that the investigator has a Significant Financial Interest related to the conduct  of the study.  
Significant Financial Interests are referred to the University Conflict of Interest Standing Committee (CISC). 
There are currently no conflicts of interest for the Principal Investigators.  
 
29.[ADDRESS_269978] results and all data 
derived from the  study.  
 
 
 
 
 
 
 
 
 
 
 
62  
 
Protocol V9.0                                                                                                                            11/2/[ADDRESS_269979]. 2015; 10:12 . Published 
2015 May 3.  DOI:10.1186/s13722 -015-0034 -5 
 
2. Bastien CH, Vallieres A, Morin CM (ISI). Validation of the Insomnia Severity Index as an outcome 
measure for insomnia research. Sleep Med. 2001 July;2(4):297 -307. DOI :10.1016/s1389 - 
9457(00)[ZIP_CODE] -4 
 
3. Bisaga A, Mannelli P, Yu M et al. Outpatient transition to extended -release injectable naltrexone 
for patients with opi[INVESTIGATOR_2427]: A phase 3 randomized trial. Drug and Alcohol Dependence  
187(1) June 2018, Pages 171 -178 https://DOI:org/10.1016/j.drugalcdep.2018.02.023  
 
4. Carnwath T, Hardman A. Randomised  double -blind comparison of lofexidine and clonidine in the 
out-patient treatment of opi[INVESTIGATOR_2533]. Drug Alcohol Depend. 1998 May 1;50(3):251 -4. 
DOI:10.1016/s0376 -8716(98)[ZIP_CODE] -4 
 
5. Evoy KE, Morrison MD & Saklad SR. Abuse and Misuse of Pregabalin and Gabapentin. Drugs 
(2017) 77: 403.  https://DOI.org/10.1007/s40265 -017-0700 -x 
 
6. Fishman M, Tirado C, Alam D et al. Safety and efficacy of lofexidine for medically managed 
opi[INVESTIGATOR_43351]: A randomized controlled clinical trial. Journal of Addiction Medicine. 2018 
published May/June 2019 - Volume 13 - Issue 3 - p 169 –176. doi:10.1097/ADM.0000000000000474  
 
7. Freynhagen R, Backonja M, Schug S et al. Pregabalin for the treatment of drug and  alcohol 
withdrawal symptoms: a comprehensive review. CNS Drugs (2016) 30:1191 –1200. DOI 
10.1007/s40263 -016-0390 -z 
 
8. Gajraj N. Pregabalin: Its pharmacology and use in pain management. Anesthesia & Analgesia.  
December 2007 - Volume 105 - Issue 6 - p 1805 -1815 . doi: 
10.1213/01.ane .[PHONE_4749].[ZIP_CODE].5e  
 
9. Gold MS et al. Clonidine & Opi[INVESTIGATOR_83637]. Lancet 1980;  1078.  
 
10. Gossop  M. The development of a Short Opi[INVESTIGATOR_2433] (SOWS). Addict Behav.  
1990;15(5):487 -90. DOI:10.1016/0306 -4603(90)[ADDRESS_269980] Rev. 2016 May 3;(5):CD002024. DOI: 
10.1002/14651858.CD002024.pub5 . 
 
12. Guo S, Manning V, Yang Y et al. Lofexidine versus diazepam for the treatment of opi[INVESTIGATOR_2581]: A double -blind randomized clinical trial in Singapore. J Subst Abuse Treat.  
2018 Aug;91:1 -11. doi: 10.1016/j.jsat.2018.04.012. Epub 2018 Apr 25. 
DOI:10.1016/j.jsat.2018.04.012  
 
13. Guy W (CGI). Guy W, Editor . ECDEU Assessment Manual for Psychopharmacology.  1976. 
Rockville, MD , U.S. Department of Health, Education, and  Welfare  
 
 
63  
 
Protocol V9.0                                                                                                                            11/2/2022  14. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 Feb; 23:56 -
62. DOI :10.1136/jnnp.23.1.56  
 
15. Hamilton M. The assessment of anxiety states by [CONTACT_35254]. Br J Med Psychol. 1959;32(1):50 -5. 
doi.org/10.1111/j.[ADDRESS_269981]. Application of random -effects pattern -mixture models for missing data 
in longitudinal studies. Psychological Methods 1997;2 (1):64 –78. https://doi.org/10.1037/[ADDRESS_269982], Waternaux C. Sample size estimation for longitudinal designs  with 
attrition. Journal of Educational and Behavioral Statistics 1999; 24:70 -93. 
DOI.org/10.3102/10769986024001070  
 
18. Hedeker D, Rose JS. The natural history of smoking: a pattern -mixture random -effects 
regression model, in: ROSE, J. S., Chassin, L., Presson, C. C. & Sherman, S. J. (Eds) Multivariate 
Applications in Substance Use Research 2000 pp. 79 –112 (Hillsdale, NJ, Lawrence Erlbaum 
Associates).  
 
19. Kahn A, Mumford JP, Rogers G Ash et al. Double -blind study of lofexidine and clonidine in the 
detoxification of opi[INVESTIGATOR_204005]. Drug Alcohol Depend. 1997 Jan 10;44(1):57 -61. 
DOI:10.1016/s0376 -8716(96)[ZIP_CODE] -6 
 
20. Kammerer N, Lemenager T, Grosshans M, Kiefer F, Hermann D. Pregabalin for the reduction of 
opi[INVESTIGATOR_48490] [in German] Psychiatr Prax. 2012;39(7):351 –352. doi: 10.1055/s -[ADDRESS_269983] MG. Selection models for repeated measurements with non ‐random dropout: an 
illustration of sensitivity 1998; 17(33): 2723 -2732. DOI:10.1002/(SICI)1097 - 
0258(19981215)17:23< 2723: AID -SIM38>3.0CO;2 -5 
 
22. Krupi[INVESTIGATOR_25195] E, Blokhina E, Zvartau E et al. Slow -release naltrexone implant versus oral 
naltrexone for improving treatment outcomes in people with HIV who are addicted to opi[INVESTIGATOR_2438]: a 
double -blind, placebo -controlled, randomised trial. Lancet HIV 2019; 6:  e221 –29 
 
23. Krupi[INVESTIGATOR_25195] E et al. A Randomized Controlled Study of the Efficacy of Pregabalin in the  Treatment 
of Opi[INVESTIGATOR_224518]. Neuroscience and Behavioral Physiology, Vol. 47, No. 9, 
November, 2017. DOI 10.1007/s11055 -017-0517 -9 
 
24. Krupi[INVESTIGATOR_25195] E, Zvartau E, Blokhina E, et al. Anhedonia, depression, anxiety, and craving in opi[INVESTIGATOR_224519]. Am J 
Drug Alcohol Abuse . 2016;42(5):614 –620. doi:10.1080/00952990.2016.1197231  
 
25. Krupi[INVESTIGATOR_25195] E et al. Injectable extended -release naltrexone for opi[INVESTIGATOR_2561]: a double -blind, 
placebo -controlled, multicentre randomised trial. The Lancet; 2011;377(9776 ): P1506 -1513. 
Doi:10.1016/S0140 -6736(11)[ZIP_CODE] -9 
 
26. Lee, JD, Friedmann, PD, Kinlock, TW et al. Extended -release naltrexone to prevent opi[INVESTIGATOR_224520]. New England Journal of Medicine2016;374 , 1232 –1242.  
 
27. Lee JD, Nunes EV Jr, Novo P, et al. Comparative effectiveness of extended -release naltrexone 
64  
 
Protocol V9.0                                                                                                                            11/2/2022  versus buprenorphine -naloxone for opi[INVESTIGATOR_224521] ( X: BOT ): a multicentre,  open -label,  
randomised controlled trial. Lancet . 2018;391([ZIP_CODE]):309 –318. doi:10.1016/S0140 -6736(17)[ZIP_CODE] - 
X 
 
28. Lin et al, 1997. Double -blind randomised controlled trial of lofexidine versus clonidine in  the 
treatment of heroin withdrawal. Drug Alcohol Depend. 1997 Nov 25;48(2):127 -33. 
DOI:10.1016/s0376 -8716(97)[ZIP_CODE] -6 
 
29. Ling W, Amass L, Shoptaw S, et al. A multi -center randomized trial of buprenorphine -naloxone 
versus clonidine for opi[INVESTIGATOR_9734]: findings from the National Institute on Drug Abuse Clinical 
Trials Network [published correction appears in Addiction. 2006 Sep ;101(9):1374]. Addiction . 
2005;100(8):1090 –1100.  doi:10.1111/j.1360 -0443. 2005. [ZIP_CODE].x  
 
30. Little, 1995. Modeling the drop -out mechanism in repeated -measures studies. Journal of 
American Statistical Association 90(431):1112 -1121.  DOI:10.2307/2291350  
31. Lucey et al. Hepatic safety of once -monthly injectable extended -release naltrexone 
administered to actively drinking alcoholics. Alcohol Clin Exp Res. 2008 Mar;32(3):498 -504. doi: 
10.1111/j.1530 -0277.2007. [ZIP_CODE]. x.  Epub 2008 Jan  30. 
 
32. McMillan & Gilmore -Thomas (VAS). Stability of opi[INVESTIGATOR_224522]. Drug Alcohol Depend. 1996 Mar;40(3):235 -9. DOI: 
10.1016/0376 -8716(96)[ZIP_CODE] -5 
 
33. Mysels et al. Mysels DJ, Cheng WY, Nunes EV, Sullivan MA. The association between 
naltrexone treatment and symptoms of depression in opi[INVESTIGATOR_48537]. Am J Drug Alcohol 
Abuse. 2011; 37:22 –26. doi:  10.3109/00952990.2010.540281.  
 
34. Pasero, 2009 (POSS). Pasero C. Assessment of sedation during opi[INVESTIGATOR_224523]. J PeriAnesthesia Nurs. 2009  Jun;24(3):186 -90. 
 
35. Runarsdottir et al. Extended -Release Injectable Naltrexone (XR -NTX) With Intensive 
Psychosocial Therapy for Amphetamine -Dependent Persons Seeking Treatment: A Placebo - 
Controlled Trial. J Addict Med. 2017 May/June;11(3):197 -204. doi: 
10.1097/ADM.0000000000000297.  
 
36. Sheehan et al. (MINI). The Mini -International Neuropsychiatric Interview (M.I.N.I.): the 
development and validation of a structured diagnostic psychiatric interview for DSM -IV and ICD -10. 
J Clin Psychiatry. 1998;[ADDRESS_269984] 20:22 -33; quiz  34-57. 
 
37. Sobell & Sobell (TLFB). Sobell, L.C. & Sobell, M.B. Timeline Follow -back: A technique for 
assessing self -reported ethanol consumption. In J. Allen & R. Z. Litten (Eds.), Measuring Alcohol 
Consumption: Psychosocial and Biological Methods 1992 (pp. 41 -72). Totowa, NJ: Humana  Press.  
 
 
38. Sullivan et al. Sullivan M, Bisaga A, Pavlicova M, et al. Long -acting injectable naltrexone 
induction: A randomized trial of outpatient opi[INVESTIGATOR_224524]. Am J Psychiatry . 2017;174(5):459 –467. doi: 
10.1176/appi.ajp .2016.16050548  
 
39. Tanum L, Solli KK, Latif ZE, et al. Effectiveness of injectable extended -release naltrexone vs 
daily buprenorphine -naloxone for opi[INVESTIGATOR_2561]: A randomized clinical noninferiority trial. 
65  
 
Protocol V9.0                                                                                                                            11/2/2022  JAMA Psychiatry . 2017;74(12):1197 –1205.  doi:10.1001/jamapsychiatry.2017.3206  
 
40. Uebelacker LA, Bailey G, Herman D, Anderson B, Stein M. Patients' Beliefs About  Medications 
are Associated with Stated Preference for Methadone, Buprenorphine, Naltrexone, or no 
Medication -Assisted Therapy Following Inpatient Opi[INVESTIGATOR_224525]. J Subst Abuse Treat. 
2016; 66:48 –53. doi: 10.1016/j.jsat .2016.02.009  
 
41. Vashchinkina et al. Addiction -related interactions of pregabalin with morphine in mice and 
humans: reinforcing and inhibiting effects. Addiction Biology . 2017;  doi:10.1111/adb.[ADDRESS_269985] to dropout. Statistical Modelling 2000;1(4):235 -269 4419 -0300 -6. DOI: 
10.1191/147108201128195  
 
43. Wesson & Ling, 2003 (COWS). The Clinical Opi[INVESTIGATOR_2433] (COWS). J Psychoactive  
Drugs. 2003 Apr -Jun;35(2):253 -9. DOI:10.1080/02791072.2003.[ADDRESS_269986], lofexidine, for opi[INVESTIGATOR_43351]. Drug Alcohol Depend. 2008 Sep 1;97(1 -2):158 -68. doi: 
10.1016/j.drugalcdep.2008.04.002. Epub 2008 May  27 
66  
 
Protocol V9.0                                                                                                                            11/2/2022  30. APPENDICES  
 
 